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1. ABSTRACT 
 
Vascular calciﬁcation is a signiﬁcant contributor to cardiovascular risk in chronic kidney 
disease (CKD) patients, and its extent and severity has been correlated with mortality in 
several studies. 
Hyperphosphatemia predisposes these patients to early and progressive vascular 
calcification: it appears to be involved in a number of mechanisms that trigger and promote 
the progression of this active and cell-mediated pathological process, in which vascular 
smooth muscle cells (VSMCs) residing in the tunica media of blood vessels are the main cell 
type actively involved. 
We developed an in vitro model to elucidate the molecular and cellular mechanisms 
involved in the pathogenesis of vascular calcification: in particular, we challenged rat VSMCs 
for 7-15 days with high Pi (inorganic phosphorous) with the purpose to reproduce in vitro 
the same pathological process that occurs in CKD patients in vivo. We investigated the high 
Pi-induced calcium deposition and the modulation of different cellular biological processes 
(apoptosis, autophagy and VSMC osteoblastic differentiation) through molecular biology, 
proteomic and immunohistochemistry analysis.  
First of all, we studied the modulation of osteonectin (SPARC), a major non collagenous 
protein of bone matrix that is associated, generally, with remodeling of tissues, 
mineralization and pathological responses to injury. Since there are controversial results 
regarding its role during the process of vascular calcification, we investigated osteonectin 
expression both in vitro and ex-vivo, and the results suggest a pro-calcifying role of this 
protein in the process of vascular calcification.  
Then, we developed an experimental strategy to delay the progression of calcium deposition 
in our in vitro model. We studied the potential effect of repeated and short time suspension 
of high Pi treatment (process that we called “Wash Out”) on the progression of calcium 
deposition, trying to reproduce the same temporal decrease of Pi levels that occurs in CKD 
patients treated with haemodialysis. Surprisingly, we discovered that it is sufficient a 
temporary total absence or partial decrease in Pi concentration under a so called “trigger 
threshold” during the process of calcification to obtain a substantial inhibition of calcium 
deposition. The molecular and cellular pathways involved in this protective action are 
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apoptosis, VSMC osteoblastic differentiation and autophagy: the formers are partially 
inhibited, while the latter is incremented after the “Wash Out” treatment. 
Finally, we investigated the mechanism of action of two drugs CKD patients are treated with 
in the attempt to reduce hyperphosphatemia and to contrast secondary 
hyperparathyroidism, respectively: Lanthanum Chloride (LaCl3) and Calindol. We 
demonstrated that these compounds significantly delay the progression of high Pi-induced 
VSMC calcium deposition, but with different mechanisms of action: both of them delay 
VSMC osteoblastic transformation, and, in particular, lanthanum chloride preserves VSMC 
lineage markers expression and partially prevents VSMC apoptosis, whereas calindol 
increases the expression of an anti-calcifying protein. 
These in vitro discoveries can suggest that vascular calcification is a multifactorial process 
that involves different cellular and molecular pathways, and that it is of relevant importance 
to control as more as possible phosphate levels in CKD patients, even with diet, because 
high-Pi is the most dangerous key regulator of vascular calcification in end stage renal 
disease pathology. 
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2.  INTRODUCTION 
 
2.1 Definition and clinical significance of vascular calcification 
In the past decade, the prevalence, significance and regulatory mechanisms of vascular 
calcification have gained increasing recognition. Over a century ago, pathologists recognized 
atherosclerotic calcification as a form of extraskeletal “ossification”. One major mechanism 
in the development of vascular calcification is similar to that of bone formation: in particular, 
vascular smooth muscle cells (VSMCs) residing in the tunica media of blood vessels undergo 
osteogenic differentiation into phenotypically distinct osteoblast-like cells. This phenotypic 
transformation involves bone morphogenetic proteins and potent osteochondrogenic 
transcription factors, and it is triggered and modulated by a variety of inflammatory, 
metabolic and genetic disorders, particularly dyslipidemia, chronic kidney disease (CKD), 
diabetes, hyperparathyroidism and osteoporosis (1).  
Calcium phosphate deposition, mostly in the form of apatite, is the hallmark of vascular 
calcification and can occur in the blood vessels, myocardium and cardiac valves. Calcium 
phosphate deposits are found in distinct layers of the blood vessels and are associated with 
specific pathologies. Intimal calcification is observed in atherosclerotic lesions (2), whereas 
medial calcification is common to the arteriosclerosis observed with age and diabetes, and is 
the major form observed in end-stage renal disease (ESRD) (3). In ESRD patients, both 
intimal and medial calcification occurs, but arterial medial calcification is by far the most 
prevalent. Thus, both intimal and medial calcifications may contribute to the morbidity and 
mortality associated with cardiovascular disease, and are likely to be major contributors to 
the 10–100 fold increase in cardiovascular mortality risk observed in ESRD patients (4).  
The exact mechanism and process of calcification within the arterial wall in ESRD is not yet 
completely understood. There is strong evidence that vascular calcification is closely 
associated with serum levels of calcium, phosphate and calcium x phosphate product (5, 6). 
Two different mechanisms are proposed to explain the relationship between calcium and 
phosphate disorders and vascular calcification: a passive one, the direct calcium-phosphate 
precipitation in the vasculature, and an active one, that induces the expression of bone-
associated genes in VSMCs, that acquire the phenotype of bone-forming (osteoblast-like) 
cells (5, 7). 
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2.2 Types of vascular calcification process 
In general, vascular calciﬁcation can be categorized into four different types: intimal 
calciﬁcation (atherosclerotic), medial calciﬁcation (calciﬁcation in tunica media), valvular 
calciﬁcation and vascular calciphylaxis (8, 9). 
Atherosclerotic calciﬁcation is a type of dystrophic calciﬁcation which can be characterized 
by cellular necrosis, inﬂammation, and lipoprotein/phospholipid complexes. In association 
with atherosclerotic plaques and old myocardial infarcts, lipid complexes, which are derived  
from cellular membranes, and serum lipoproteins nucleate calcium deposition. Endothelial 
cell dysfunction drives additional lipid deposition through providing a thrombogenic surface 
which, in turn, provides ﬁbrin and platelet derived phospholipids. Following the 
degenerative tissue calciﬁcation, calciﬁed cartilage forms via a vascular remodeling process 
through endochondral ossiﬁcation process. It is a patchy and discontinuous process that 
involves macrophages and VSMCs in lipid-rich regions (8, 10). 
Medial calciﬁcation usually occurs in the absence of lipid and is associated with α-smooth 
muscle actin-positive VSMCs (9). It is an intramembranous ossiﬁcation process of the arterial 
tunica media, which resembles bone formation and odontogenesis (8). It does not require 
any cartilaginous precursor, and BMP2/Msx2 dependent signaling is a central feature of the 
mineral formation (8). It is focal in distribution, organized along the elastic lamellae, and is 
almost exclusively associated with VSMCs. Moreover, it has been reported by multiple 
researchers that vascular calciﬁcation is initially triggered by matrix vesicles in association 
with ﬁbrillar collagen extracellular matrix (8, 11). 
The differences between intimal and medial calciﬁcation imply different etiologies; however, 
a common feature of both forms of calciﬁcation is the presence of VSMCs (12). 
Cardiac valve calciﬁcation is known to be induced by mechanical stress and inﬂammation, 
which is followed by dystrophic mineralization and intramembranous ossiﬁcation in 
association with endochondral ossiﬁcation (although to a lesser extent compared to that of 
the atherosclerotic calciﬁcation) (8, 13). It is believed that aortic valve calciﬁcation is strongly 
related to aging in many cases where, degenerative calciﬁcation, which is the most common 
cause of aortic stenosis in patients older than 70 years, is observed (13). 
Vascular  calciphylaxis,  also  known  as  calciﬁc  uremic  arteriolopathy, usually occurs in 
patients with secondary hyperparathyroidism and renal insufﬁciency, especially those 
5 
 
withend-stage renal hemodialysis (14, 15). From a biochemical point of view, it occurs when 
the physiological calcium-phosphate solubility (60 mg2/dl2) level is exceeded, exhibiting 
widespread deposition of amorphous calcium phosphate (10). However, certain case reports 
describe the occurrence of the syndrome in patients with normal renal and parathyroid 
function, and no abnormalities in calcium and phosphorous level (14). 
 
2.3 Vascular calcification is an actively regulated process 
For many years, vascular and soft-tissue calciﬁcation were thought to occur predominantly 
by a passive, unregulated physicochemical mechanism and to represent a degenerative, 
irreversible process of aging (16). However, as early as the 19th century, Virchow described 
bone-like structures in the vasculature, which provided the ﬁrst clue that vascular 
calciﬁcation may be a regulated process. Converging evidence from in vivo analyses of 
histopathology and gene expression in human vessels, as well as animal knockout models, 
and analysis of human genetic defects all support the hypothesis that vascular calciﬁcation is 
an active, cell-mediated process (17). Over the past ten years, our understanding of 
molecules and processes that regulate ectopic calcification has grown exponentially. Much 
of our understanding comes from identification of genes through linkage or targeted 
deletion studies that cause human and/or mouse ectopic calcification disorders, respectively 
(18). 
Vascular calcification, like bone formation, is a highly regulated process, involving both 
inductive and inhibitory processes (19). Cells derived from the tunica media, including 
VSMCs, adventitial fibroblasts, and pericytes, undergo osteochondrogenic differentiation 
and matrix mineralization under the appropriate conditions in vitro (20-24). These studies 
suggest that cell-mediated processes tightly control procalcific and anticalcific mediators in 
the artery, so that ectopic calcification is normally avoided. Under pathological conditions, 
this balance is upset and leads to ectopic mineralization. 
Many studies have shown that the mineral deposited in the vessel wall is basic calcium 
phosphate in apatitic form, some of which is hydroxyapatite [Ca10(PO4)6(OH)2], the same 
crystal  found  in  bone. Moreover, VSMCs in vivo have been observed to bud matrix vesicles 
from their plasma membrane, ﬁrst described in chondrocytes and osteoblasts during 
developmental osteogenesis, that form a microenvironment capable of concentrating 
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calcium and phosphate, thus allowing crystal nucleation to occur (12). However, while 
skeletal mineralization is a regulated process induced by complex, well-timed developmental 
cues, vascular calciﬁcation is a pathological process, occurring in response to dysregulated 
environmental cues.  
Under normal conditions, inhibitors of soft-tissue mineralization, such as matrix γ-
carboxyglutamic acid protein (MGP), are expressed locally within the vessel wall while 
others, such as fetuin-A, are present in the circulation. Down-regulation or perturbation of 
these proteins leads to a phenotypic transformation of VSMCs into osteo⁄chondrocytic-like 
cells that have the capacity to modulate the mineralization process (1).  
Local  VSMCs, as  well as circulating mesenchymal stem cells, local pericytes and ﬁbroblasts 
that exhibit multilineage potential, may transdifferentiate into osteo/chondrocytic cells in 
the arterial wall and orchestrate bone formation and calciﬁcation. The osteo/chondrocytic 
conversion of VSMCs and stem cells both in vitro and in vivo is accompanied by up-regulation 
of Cbfa1/Runx2, osterix, Msx2 and Sox9, transcription factors that are centrally involved in 
chondrocyte maturation and osteoblastic differentiation (1).    
Accumulating evidences suggest that multiple factors, such as hypertension, reactive oxygen 
species, advanced glycation end products, lipids, inﬂammatory proteins, such as tumor 
necrosis factor-α, and potentially others, like high phosphorous (Pi) levels and yet 
unidentiﬁed damage-inducing agents, initiate osteo/chondrocytic conversion and matrix 
vesicles release in VSMCs (25).   
The current major theories and regulators of vascular calcification include 1) loss of 
inhibition, 2) induction of osteochondrogenesis, 3) apoptosis, 4) abnormal calcium and 
phosphate homeostasis, 5) circulating nucleation complexes/paracrine factors derived from 
bone and 6) matrix degradation (18) (Fig. A). 
Studies  in  animal  models  have  provided  important insights  into  the  pathogenesis  of  
vascular  calciﬁcation, but approaches to stop progression or even reverse the pathology are 
in their infancy. One key area for further investigation is the role of circulating proteins in 
regulating calciﬁcation, either by effects on maintenance of calcium phosphate homeostasis 
in solution or by direct effects on vascular cell function.  
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Figure A: Cellular and Molecular Mechanisms of Vascular Calcification 
Six different mechanisms that have been proposed to regulate the initiation or progression of 
vascular calcification (18). 
 
2.3.1 Inducers of vascular calciﬁcation 
Core Binding Factor α-1 (CBFA-1) 
Cbfα-1  is  a  pivotal transcriptional regulator of osteogenesis and plays a crucial role in the 
lineage determination of connective tissue progenitor cells. VSMCs and osteoblasts are 
derived from mesenchymal precursor cells, and Cbfα-1 can induce osteoblastic 
differentiation in both cell types. Cbfα-1 is up-regulated in calciﬁed human atherosclerotic 
plaques and human VSMCs in vitro along with other osteoblastic and chondrocytic markers 
(e.g. osteocalcin, alkaline phosphatase and bone sialoprotein) that are under its regulation 
(26). Expression of this plethora of mineralization-regulating proteins by VSMCs may 
represent an attempt by the cells to further regulate the calciﬁcation process; however, the  
exact  role  of these multifunctional proteins in the vasculature remains unknown (12).  
 
Bone Morphogenetic Protein (BMP)-2 and -4 
These proteins are inflammatory mediators in vascular endothelium responsive to disturbed  
flow, increased oxidative stress and inflammation. Increased BMP activity enhances 
atherogenesis and vascular calcification (27, 28).  
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The BMPs belong to the transforming growth factor (TGF)-β superfamily and elicit their 
response via the so-called type I and II receptors. BMP-2 and -4 interact with the activin-like 
kinase receptor ALK2, ALK3 and ALK6, which are type I receptors that form complexes with 
the BMP type II receptor (BMPRII). In canonical BMP signaling, the receptors phosphorylate 
specific regulated (R)-SMAD proteins, which translocate into the nucleus and regulate gene 
transcription. SMAD1/5/8 mediate BMP-signaling, whereas SMAD2/3 mediate TGF-β 
signaling (29).  
The high BMP activity was associated with a remarkable increase in aortic expression of  
osteogenic markers and calcification. Increased BMP inhibition, as mediated by a MGP 
transgene, limited these changes (29). 
 
Other pro-calcific proteins 
Muscle Segment Homeobox-2 (MSX2) 
It appears to be a critical gene in vascular calcification up-regulated by the action of BMP-2.  
MSX2 is a member of the homeobox gene family and plays an important role in bone 
formation and temporal spatial timing of osteoblast differentiation. The mineralization 
process of tunica media calcification is akin to intramembranous bone formation, and 
studies demonstrate MSX2 expression and function in vascular media calcification. The 
effect of MSX2 is through up-regulation of osterix (Osx), a global transcriptional regulator of 
mineralization and osteoblast differentiation (30). 
 
Osterix (Osx)/Sp7  
It is a member of the Sp1 transcription factor family, plays an essential role in bone 
formation and osteoblastogenesis. Although Osterix has been shown to be induced by BMP2 
in a mesenchymal cell line, the molecular basis of the regulation, expression and function of 
this protein during osteoblast differentiation is not fully understood. To date, the target 
genes of osterix have not been identified. Interestingly, it promotes osteoblast 
differentiation of Runx2-deficient mesenchymal cells in association with up-regulation of 
several genes, which are not up-regulated by Runx2. Therefore, identification of the genes 
that are regulated by Osterix and that play critical roles in osteoblastogenesis may advance 
the understanding of the molecular mechanism by which BMP2 regulates bone formation 
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and osteoblastogenesis and may contribute to developing therapeutic agents for bone 
diseases (25). 
 
2.3.2 Inhibitors of vascular calciﬁcation 
Matrix Gla Protein (MGP) and Growth Arrest Specific Gene 6 (Gas-6) 
They are two particularly important Vitamin-K Dependent Proteins (VKDPs), and their roles 
in vascular biology are just beginning to be understood. Both are produced by VSMCs and 
function to protect the vasculature: MGP prevents vascular calcification and Gas-6 affects 
VSMCs apoptosis (31).  
Together, these proteins constitute a new mechanism of local vascular regulation, where the  
blood vessel defends itself against injury and participates in self-repair. A failure of these 
local mechanisms might be an important first step in a cascade of events culminating in 
vascular calcification, and supports the notion that vascular calcification is an active, 
regulated process. 
To become biologically active, both MGP and Gas-6 undergo carboxylation, a process that 
occurs at the blood vessel level (31). Like hepatic carboxylation, this peripheral carboxylation 
is inhibited by the administration of warfarin, yet whereas warfarin’s anticoagulant effect is 
well known, its effect on the vasculature is less certain. 
Produced by many cells types and binding to one of three receptors (Tyro3, Axl, or Mertk), 
Gas-6 has widespread physiologic roles, important in inflammation, renal disease, sepsis, 
and neoplasia (32). Gas-6 produced by VSMCs seems to have a pro-survival effect: by binding 
to its receptor Axl, it stimulates the anti-apoptotic protein Bcl-2 and inhibits the 
proapoptotic protein caspase 3, ultimately conferring a state of longevity to the cell (33). 
Indeed, recent in vitro studies have shown Gas-6 prevents vascular calcification. In a model 
of phosphate-induced vascular calcification, Son et al. have shown that Gas-6 prevents 
vascular smooth  muscle  cell  apoptosis  and  calcification  in  a  dose-dependent  manner  
(34). Elevated  phosphate  levels  directly suppressed Gas-6 activity (35). These findings raise 
fascinating questions about the mechanisms of vascular calcification. As originally suggested 
by Proudfoot et al., whose important work showed that vascular smooth muscle cells 
develop apoptotic bodies before calcium crystals, apoptosis may be the critical first step, 
with calcification as a secondary phenomenon of dying cells (36). 
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MGP also has important functions in vascular biology. It is produced in bone and VSMCs, and 
prevents vascular calcification. Its clinical importance is evidenced by the development of 
widespread and extensive vascular calcification in MGP knockout mice, which is prevented if 
arterial MGP expression is genetically restored (37). In humans, a rare genetic disorder 
resulting from mutations in the MGP gene, Keutel syndrome, is associated with extensive 
soft tissue calcification and vascular calcification (38). In postmortem evaluation, calcium 
deposition is primarily located within the media of the vessel wall, specifically the elastic 
interna, with little intimal involvement. The potential role of MGP polymorphisms in vascular 
calcification is not fully known yet raises interesting questions about genetic susceptibility to 
vascular calcification (39). MGP plays a crucial role in preventing the calciﬁcation of arteries: 
paradoxically, MGP expression is up-regulated in calciﬁed human plaque, probably through a 
negative feedback mechanism in response to calciﬁcation (12). 
Despite the clinical importance of MGP in preventing vascular calcification, its exact 
mechanism of action remains unknown. MGP complexes with ambient calcium, preventing 
calcium supersaturation and crystallization within vessel walls and, by binding to 
hydroxyapatite crystals, inhibits their crystalline growth. MGP also inhibits VSMCs from 
dedifferentiating into osteoblast-like cells, a well-established mechanism for vascular 
calcification. Recent studies suggest that the activity of MGP is affected by BMP-2: higher 
levels of MGP will inhibit BMP-2 activity (40, 41). 
Namely, as part of the VKDP family, both Gas-6 and MGP must be converted to their 
functional forms by undergoing carboxylation. Thus, in addition to the  expression of these 
proteins, the structural form determines functional activity. 
The process of converting VKDPs to their biologically active forms requires the carboxylation 
of glutamic acid residues, a complex and incompletely understood process involving multiple  
enzymes  (31).  As  a  final  step, γ -glutamyl  carboxylase (GGC) facilitates the addition of a 
CO2 molecule to the γ-carbon of glutamic acid, forming γ-carboxyglutamic acid. This requires 
the presence of the reduced form of vitamin K. Because vitamin K naturally occurs in the 
oxidized form, it must be converted into a reduced form, a reaction catalyzed by vitamin K 
epoxide reductase (VKOR). In this process of carboxylation, vitamin K is returned to its 
oxidized state, and a cycle of vitamin K reuse ensues. Warfarin, which shares a common ring 
structure with vitamin K, interferes with VKOR, interrupts vitamin K recycling, prevents 
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further γ-carboxylation, and ultimately leads to a deficiency of active VKDPs. Ultimately, the 
complexity of the carboxylation process, with multiple enzymatic reactions and many 
polymorphisms of participating gene products, leads to a wide range of VKDP phenotypes, 
and, partly, explains the variation in  individual susceptibility to warfarin. 
Important studies by Murshed et al. have shown that, although the liver makes MGP, such 
hepatic production does not protect against vascular calcification; rather, the protein must 
be locally produced within the vasculature (37). This tissue localization might explain why 
serum levels of MGP do not correlate with its biologic activity. In addition, the process of 
carboxylation differs between the liver and the periphery. The activity of VKOR, the enzyme 
responsible for vitamin K recycling, is three times higher in vascular smooth muscle cells 
than in the liver, suggesting that peripheral carboxylation may be more dependent on 
adequate stores of vitamin K (31).  
Schurgers et al. have illuminated the critical importance of post-translational carboxylation 
of peripheral VKDPs (42). Although both normal and calcified vessels express MGP, normal 
vessels have a predominance of carboxylated MGP, whereas calcified vessels have a 
predominance of the uncarboxylated version (42). It seems that the ratio of carboxylated to 
uncarboxylated protein  ultimately determines biologic activity of both MGP and Gas-6 (43).  
These findings suggest a potential mechanism: to help protect blood vessels from injury, 
vascular smooth muscle cells continuously produce MGP and Gas-6, which then undergo 
carboxylation. The carboyxlated proteins form a defense against injury: MGP preventing 
crystalline supersaturation and Gas-6 regulating both apoptosis and migration of smooth 
muscle cells into areas of injury. Failure to activate these proteins leads to vascular injury.   
In summary, Gas-6 and MGP provide local protective mechanisms, influencing cell death and 
calcification, and support the notion that the blood vessels themselves actively participate in 
their own defense (31). 
 
Osteonectin (ON) 
Osteonectin, also named SPARC (secreted protein, acidic and rich in cysteine), is a widely 
expressed profibrotic protein with pleiotropic roles. It is a calcium-binding matricellular 
protein present in skeletal tissue, where, rather than playing structural roles, primarly serves 
as biological modulator (44). The function of osteonectin in the skeleton relates to bone cell 
differentiation, control of remodelling and maintenance of bone mass (45). SPARC-deficient 
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mice have decreased bone formation and decreased osteoblast and osteoclast surface and 
number, which leads to a decrease in bone formation and remodeling, with a negative bone 
balance that causes profound osteopenia and severe cataract formation (46). 
Beyond bone, osteonectin has been found in many tissue undergoing morphogenesis or 
remodelling, where it is expressed and secreted by different cellular types such as 
fibroblasts, endothelial cells, VSMCs and tumour cells.  
In different tissues, osteonectin is able to regulate cell migration, cell proliferation, tissue 
morphogenesis and tissue repair even if its effects are cell type-dependent (44, 47). For 
example, the regulatory role of osteonectin in angiogenesis is supported by the increase of 
its expression in the vasculature during physiological and pathological angiogenesis and by 
the modulatory activity that this protein exerts on growth factors involved in the 
angiogenesis process such as VEGF, FGF2 and TGF-β (48). Besides angiogenesis, there are 
evidences that link osteonectin to obesity and diabetes mellitus. In fact, osteonectin is 
associated with diabetes complications such as diabetic retinopathy and nephropathy, 
conditions that are ameliorated in the SPARC-knockout mouse model and, as a regulator of 
the extracellular matrix, osteonectin also contributes to adipose-tissue fibrosis. (49). 
Regarding tumours, osteonectin modulate the interaction between tumour cells and the 
normal surrounding cells, affecting proliferation, survival and migration of cancer cells, 
tumour invasion and metastasis (50).  
Regarding vascular calcification, osteonectin is present in VSMCs (51) and its expression has 
been found to be modulated in calcified arteries (52, 46, 53, 54). Moreover, osteonectin is 
also one of the most potent inhibitors of hydroxyapatite crystal formation in vitro (55, 56), 
but, despite this action, osteonectin deficient mice do not exhibit arterial calcification (57). 
Thus, osteonectin is expressed in VSMCs, but its role in vascular calcification is not well 
elucidated.  
Osteonectin expression has been investigated predominantly in ex vivo studies on human 
arteries. Shanahan et al demonstrated that VSMCs in normal arteries express SPARC at high 
levels, however, in Mönckeberg's Sclerosis (MS) arteries (tunica media calcification), there 
was a significant reduction in the level of this protein expression. The high expression of 
SPARC in the normal vasculature and its absence in MS lesions suggest that its loss may 
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promote mineralization (52). However, Bini et al demonstrated the presence of osteonectin 
in association with large calciﬁcations in atherosclerotic plaques (58).  
The lack of knowledge on osteonectin does not allow to deﬁne its speciﬁc role. Further 
investigations are needed to precise its utility in calciﬁcation assessment. 
 
Other anti-calcific proteins 
Bone Morphogenetic Protein -7 (BMP-7) 
It is an important regulator of skeletal modeling, restores skeletal anabolic balance, reduces 
serum phosphate levels, and, thereby, also reduces vascular calciﬁcation in experimental 
animal models of CKD, highlighting the importance of maintaining a balance in signaling in 
the vasculature during development and in disease (12). 
 
Fetuin-A 
All extracellular ﬂuids, even under normal circumstances, are saturated with respect to 
calcium and phosphate, suggesting that potent inhibitors of vascular calciﬁcation are 
normally circulating to prevent ectopic soft-tissue calciﬁcation. The serum protein fetuin-A 
(a-2-Heremans–Schmid glycoprotein) is a key component of VSMCs-derived vesicles. It is a 
very potent inhibitor of apatite crystal formation in solutions containing calcium and 
phosphate and thus serves to maintain the solubility of calcium in plasma (12). Fetuin-A can 
inhibit apoptosis and enhance phagocytosis, and its incorporation into vesicles completely 
abrogates their ability to calcify. 
Inﬂammation reduces fetuin-A synthesis, and it has been shown that, in hemodialysis 
patients, the fetuin-A levels are signiﬁcantly lower than in healthy controls  and  are  
inversely  related  to  C-reactive  protein (59, 60). At sites of vascular damage, it is taken up 
by VSMCs, incorporated into intracellular vesicles and  then released within matrix vesicles, 
where it potently inhibits mineral nucleation.   
Hence, fetuin-A may inhibit the pro-calciﬁc effects of mineral imbalance in normal arteries, 
and reduced levels in CKD contribute to induction of calciﬁcation (12). 
 
Osteopontin (OPN) 
OPN may affect calciﬁcation by stimulating resorption: by binding to avb3 integrin on 
osteoclasts, it leads to a decrease in cytosolic calcium, resulting in osteoclast activation to a 
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resorptive phenotype (61). This binding may also promote resorption of ectopic calciﬁcation 
by inducing expression of carbonic anhydrase isoenzyme II (CA II) in macrophages, which is 
key in creating the acidic environment required for resorption (12). 
Although OPN is not present in most normal soft tissues, it is abundant at sites of ectopic 
calcification in human atherosclerotic lesions, diabetic arteries, uremic arteriolopathy and 
valves. OPN has a high content of aspartic acid residues and is highly phosphorylated on 
serine and threonine residues: this structure enables OPN to bind to hydroxyapatite and 
calcium ions, and, thus, to physically inhibit crystal formation and growth in vitro (62). 
 
2.3.3 Other regulators 
The role of pH in promoting or inhibiting calciﬁcation is also important; crystal growth is 
favored in an alkaline medium. The carbonic anhydrase isoenzyme II (CA II) knockout mouse 
develops an age-dependent medial calciﬁcation of small arteries in a number of organs, with 
the male genital tract developing the most extensive arterial calcinosis  (63). CA II deﬁciency 
in humans causes a rare autosomal recessive disorder characterized by osteopetrosis, renal 
tubular acidosis and cerebral calciﬁcation (64). 
Perturbation of the pathway involved in the generation of pyrophosphate by inactivation of 
the enzyme ecto-nucleotidepyrophosphatase⁄phosphodiesterase 1 (ENPP1) leads to 
ossiﬁcation of the aorta. The mouse knockout for ENPP1 develops up-regulated alkaline 
phosphatase, decreased expression of OPN, increased calciﬁcation of aortic smooth muscle 
cells and chondrogenesis in mesenchymal precursors. In humans, mutations in ENPP1 cause 
infantile idiopathic arterial calciﬁcation, a condition in which the internal elastic lamina of 
muscular arteries calciﬁes resulting in death usually within the ﬁrst year of life (65, 66). 
Finally, there are a number of other factors that may speciﬁcally contribute to the procalciﬁc  
environment observed in CKD patients. Parathyroid hormone can cause hypercalcemia, and 
active vitamin D3 (1,25-di-hydroxy vitamin D3), which is routinely used in the management 
of secondary hyperparathyroidism, itself contributes to ectopic calciﬁcation in both animal 
models and in vitro. However, the role these factors play in calciﬁcation is likely to be 
complex as they may have both concentration and temporal effects on both bone and 
vascular function with both too much, or too little, being harmful (12). 
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2.4 Vascular calcification and chronic kidney disease (CKD) 
The clinical condition associated with major severe vascular calciﬁcation is end-stage renal 
disease, in which evidence points to inorganic phosphate (Pi) as central regulator. ESRD 
patients are often hyperphosphatemic, deﬁned as a phosphate concentration higher than 2 
mM, compared with 1–1.5 mM in healthy patients (25). 
Uremic toxins present in the uremic milieu, such as a mineral imbalance, and the disruption 
of circulating and cellular inhibitors of calcium and phosphate precipitation induce VSMCs 
apoptosis, and vesicle release resulting in mineral nucleation and deposition of 
hydroxyapatite (1). 
Among the 25 million American patients with stage 2–5 chronic kidney disease (CKD), 
cardiovascular disease causes a disproportionately high mortality risk. Patients with CKD are 
more likely to die (often of cardiovascular causes) than to progress to dialysis (67). The risk 
of death is especially high in late-stage kidney disease; a 30-year-old patient with end-stage 
renal disease faces an equivalent risk of death to a 90-year-old without CKD (18). CKD 
patients have a 30-fold higher mortality than the general population despite adjustment for 
traditional cardiovascular risk factors, such as diabetes mellitus and hypertension (68).  
Recent epidemiological studies have shown that even minimal alterations in renal function 
(as evidenced by a reduced glomerular ﬁltration rate, presence of microalbuminuria and 
elevated serum phosphate levels in the general population) are associated with a high 
cardiovascular risks (69). 
Vascular calciﬁcation is a signiﬁcant contributor to cardiovascular risk in CKD patients, and its 
extent and severity has been correlated with mortality in several studies (12). 
The precise pathophysiology of vascular calcification in end-stage renal disease is unknown, 
but risk factors include age, hypertension, time on dialysis, and, most significant, 
abnormalities in calcium and phosphate metabolism (70-72). 
Calciﬁcation of arteries occurs in the intima in association with atherosclerosis, where it may 
contribute to plaque formation and rupture, and in the media, where it causes vascular 
stiffening.  
Although a combination of intimal and medial calciﬁcation may occur in patients with CKD, 
either process may occur independently of the other, and, at least in adolescents and young 
adults with CKD, the vascular ‘calcium load’ is almost exclusively medial. Increased arterial 
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stiffness is mechanistically linked with systolic hypertension, left ventricular hypertrophy, 
and reduced coronary perfusion, and is a signiﬁcant independent predictor of mortality (53).  
CKD is associated with fatal cardiovascular consequences in part due to ectopic calcification 
of soft tissues particularly arteries, capillaries and cardiac valves. 
As above mentioned, an increasing body of evidence from experimental studies and in vivo  
data suggest that (I) a mineral imbalance with hyperphosphatemia and high-circulating 
calcium x phosphate product, (II) a deficiency of systemic or local calcification inhibitors, (III) 
death or damage of vascular smooth muscle cells, and/or (IV) phenotypic transformation of 
VSMCs to osteo/chondrocytic cells may all act in concert to initiate and sustain vascular 
calcification (12).  
However, in CKD a mineral imbalance is central to this damage with elevated phosphate 
inducing expression of Runx2 and osterix in VSMCs. More signiﬁcantly, apoptotic bodies and 
matrix vesicles similar to those that nucleate mineral in bone are released  from dying and 
damaged VSMCs and nucleate mineral in vascular tissues (36). 
The devastating effects of CKD on the vasculature are the net result of multiple pathogenic  
mechanisms that overwhelm natural defenses against calciﬁcation. Circulating toxic 
elements that cause VSMC damage and death accumulate, while calciﬁcation inhibitors are 
decreased both locally and systemically (12).  
Studies with genetically altered mice have identified both local and systemic calcification 
inhibitors that act to maintain VSMC differentiation or regulate vesicle properties. However, 
for many of these proteins, the mechanisms and sites of action are still under investigation. 
In particular, it is unclear whether factors present in the circulation have an inhibitory role 
there and whether circulating levels of these proteins influence or are indicative of 
underlying disease processes in individual patients. A greater understanding of the origins 
and roles of potential circulating inhibitors may result in novel strategies aimed at the 
prevention or reversal of the life-limiting calcifying vasculopathies seen in CKD patients (12), 
and a better understanding of the complex mechanisms regulating tissue calciﬁcation may 
have therapeutic potential in reducing the cardiovascular disease-associated  morbidity  and  
mortality  in  patients  with  renal disease. 
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2.4.1 Mineral imbalance: the role of calcium and phosphate 
Normal serum concentrations of Ca and inorganic P ions are metastable with respect to 
basic calcium phosphate (BCP; a mixture of octacalcium phosphate, dicalcium phosphate 
dihydrate and apatite) precipitation, but can support growth of nascent crystals. In ESRD 
condition, systemic Ca and inorganic P concentrations typically exceed 2.4 and 2.0 mM, 
respectively (71). Consequently, calcification has traditionally been ascribed to 
supersaturation and subsequent precipitation of mineral ions. This has led to therapeutic 
measures to reduce the Ca/P product aimed mostly at reduction of P (70). 
More recently, in vitro models have been developed to determine the factors speciﬁc to CKD 
that might induce VSMCs calciﬁcation. Exposure of VSMCs to media containing elevated 
levels of calcium or phosphate rapidly induced calciﬁcation, with synergistic effects if both 
ions were elevated (70). Apoptosis accounted for part of the accelerated calciﬁcation 
observed in this model: however, in response to extracellular calcium, viable VSMCs were 
induced to release vesicles that contained preformed calcium-phosphate apatite accounting 
for their increased calciﬁcation capacity in vitro (12, 70). Interestingly, micro- or nano-scale 
hydroxyapatite and other calcium phosphate crystals may also have the ability to regulate 
cell phenotype (25, 73, 74). Elevated calcium  induces  VSMC death  and  increases  matrix  
vesicle release,  whereas  calcium and phosphate both increase the mineralization potential 
of the released matrix vesicles. Figure B offers a complete description of vascular 
calcification process. 
The disturbances in mineral metabolism in CKD possibly have similar effects in vivo (75). The 
heightened state of supersaturation that exists in plasma favors the deposition of mineral in 
soft tissues, including the blood vessels and cardiac valves, by promoting vesicle release and 
VSMCs osteogenic differentiation (12). 
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Figure B: Vascular calcification is mediated by vascular smooth muscle cells  
Alterations in calcium (Ca) and phosphate (P) levels or vascular insult lead to osteogenic/chondrogenic 
conversion of VSMCs in the vascular wall. This is associated with dramatic loss of mineralization inhibitors, 
 the production of calcifying matrix vesicles, and extracellular matrix (ECM) degradation. In addition, Ca 
and P induce VSMC apoptosis and release of apoptotic bodies, which, in turn, form the initial nidus  
for vascular calcification (76). 
 
 
2.5  VSMCs: a model system to investigate mechanisms of vascular calcification in vitro 
Vascular smooth muscle cells represent a validated in vitro model to investigate cellular and 
molecular mechanisms involved in the pathogenesis of vascular calcification (12). They 
normally reside in the media of blood vessels in a differentiated state and are responsible for 
regulating vascular tone. They exhibit a contractile phenotype and highly express genes that 
are required for the maintenance of myofilament structure and function. These genes 
include α-actin, Smooth Muscle 22α (SM22α) and Smooth Muscle-myosin heavy chain (77). 
However, VSMC phenotype is characterized by the ability to reversibly enter in a synthetic 
state of proliferation and production of large amounts of extracellular matrix. Transition into 
the synthetic state is associated with a loss of smooth muscle cell markers associated with 
contractility: so, VSMCs can be activated from a quiescent, differentiated state into an 
actively proliferating and synthesizing phenotype. This phenotypic change is associated with 
loss of smooth muscle cell markers and can be induced by various stimuli in vitro, including 
various growth factors, injury, or mechanical stress (77). This transition is thought to play a 
role in the pathogenesis of atherosclerosis and Mönckeberg's Sclerosis, because both are 
associated with decreased expression of VSMC markers in plaques and areas of calcification 
(30). VSMCs play a key role in inhibiting calciﬁcation in the normal vessel, but features 
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associated with vascular pathological environments  impinge on their normal function, 
induce damage and cause osteogenic phenotypic change that favors the deposition of 
mineral (12, 53). 
VSMCs are thought to be the predominant cells associated with medial calcification, in 
contrast to intimal calcification, which also involves lipids and inflammatory cells. A number 
of studies have shown that VSMCs cultured with high phosphate can undergo calcification in 
vitro, that involves the phenotypic transition to osteoblastic, chondrocytic, and osteocytic 
cells. This in vitro model has been widely used for investigating the cellular and molecular 
mechanisms responsible for vascular calcification (78).  
 
2.6 The role of phosphorus in the development and progression of vascular calcification 
Although much progress has been made in the past five years in understanding the 
mechanisms leading to accelerated vascular calcification in patients with CKD, it remains 
unclear how an environment high in phosphate can impinge so significantly on the 
calcification process (79). 
In CKD population, vascular calcification is associated with additional non-traditional factors 
that may be unique to CKD and thus predispose these patients to early and more 
accelerated calcification (80). One such factor is serum phosphorus, which has been linked to 
vascular calcification in several studies and is emerging as a key regulator of calcification in 
the CKD population (72, 81-83). In vitro studies and animal models of vascular calciﬁcation 
suggest that Pi not only participates in hydroxyapatite crystal formation, but, also, directly 
induces osteogenic gene expression when applied at concentrations similar to those in 
hyperphosphatemic subjects in vivo (84, 85). 
Hyperphosphatemia predisposes these patients to early and progressive vascular 
calcification: it appears to be involved in a number of mechanisms that trigger and promote 
the progression of vascular calcification, including (1) transition of VSMCs from a contractile 
to an osteochondrogenic phenotype and mineralization of VSMC matrix through sodium-
dependent phosphate cotransporters, (2) induction of VSMC apoptosis, (3) inhibition of 
monocyte/macrophage differentiation into osteoclast-like cells, (4) elevation of fibroblast 
growth factor 23 levels, and (5) decreases in Klotho expression.  
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Whether vascular calcification can be prevented or reversed with strategies aimed at 
maintaining phosphate homeostasis presently is unknown (83).  
 
2.6.1 Phosphate and osteochondrogenic phenotypic change in VSMCs 
To determine whether phosphorus directly affects vascular calcification, several in vitro 
studies have been performed using VSMCs. When VSMCs are exposed to high levels of 
inorganic phosphate, consistent with levels seen with hyperphosphatemia, calcification is 
induced in the extracellular matrix surrounding the VSMCs (86). This calcification has 
features similar to calcification that occurs in bone, including matrix vesicles and bioapatite 
synthesis (20). Furthermore, phosphate directly induces phenotypic changes in VSMCs, 
causing them to transform from a contractile phenotype into an osteochondrogenic 
phenotype. When VSMCs are exposed to elevated phosphate concentrations in vitro, there 
is increased gene transcription of messenger RNAs encoding proteins involved in matrix 
mineralization and bone formation, such as osteocalcin and Cbfα-1/RUNX2 and 
simultaneous down-regulation of transcription factors for smooth muscle cells (53, 87). 
Notably, these changes also occur in human and animal models of calcification (83). 
In vitro studies have  examined the response of cultured human aortic smooth muscle cells 
to different levels of extracellular Pi and have demonstrated that cells exposed to Pi levels 
similar to those seen in uremic patients (> 1.4 mM) showed dose-dependent increases in cell 
culture calcium deposition. The results of this study also defined the role of elevated 
phosphate in transforming the vascular phenotype of these cells to an osteogenic 
phenotype, such that a predisposition for calcification was created. Similarly, in a study of 
bovine aortic VSMCs, mineralization of VSMCs in culture was associated with the dramatic 
loss of smooth muscle-specific gene expression (smooth muscle lineage markers SM22 and 
α-smooth muscle actin) in the presence of an organic phosphate donor, β-glycero phosphate 
(75). A third study (88) has shown that medial cells from calcified arteries of matrix gla-
protein (a calcification inhibitor) null mice express high levels of osteopontin and Cbfα-1, as 
well as decreased levels of α-smooth muscle actin, when compared with VSMCs from non-
calcified wild-type blood vessels. It is interesting that evidences for similar expression 
patterns in calcified human arteries of patients with calcific uremic arteriolopathy have 
recently been reported (89). These data support the concept that VSMCs undergo 
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phenotypic conversion to osteogenic cell type in the presence of hyperphosphatemia in both 
animals and humans. Similarly in the bone, Cbfα-1 seems to be a key regulatory factor in 
vascular calcification, being up-regulated by uremic toxins in dialysis patients (90). For 
example, calcified inferior epigastric arteries from dialysis patients express Cbfα-1/RUNX2 
and osteopontin in both the media and intima layers (2). Giachelli et al hypothesized that 
this phenotypic change in VSMCs may serve to repair or adapt to a mineralizing 
environment, given the increased expression of several mineral-regulating molecules in the 
VSMCs (86). The mechanisms responsible for controlling this phosphate-induced phenotypic 
change currently are not completed elucidated (83). An hypothesis is that the effects of 
hyperphosphatemia are mediated by a sodium-dependent phosphate co-transporter (NPC), 
that facilitates entry of Pi into vascular cells (87). This intracellular influx is increased during 
hyperphosphatemia, as seen in uremic patients, and leads to the accumulation of 
intracellular phosphate. By pathways that have not yet been fully elucidated, the increased 
intracellular phosphate serves as a signal for osteogenic gene expression (Cbfα-1 and 
downstream targets osteopontin and osteocalcin) and as a suppressor of VSMC specific gene 
expression (smooth muscle lineage markers SM22 and α-smooth muscle actin), resulting in 
increased secretion of mineral-nucleating molecules (matrix vesicles, calcium-binding 
proteins, alkaline phosphatase and collagen-rich extracellular matrix). These factors combine 
to transform the cell to be susceptible to vascular calcification (75, 90). 
 
2.6.2 Phosphate-induced apoptosis in VSMCs 
Some studies found a link between apoptosis of VSMCs and vascular calcification: it has 
been suggested that apoptosis is a key regulator of VSMC calcification (36, 83, 91, 92). 
Matrix vesicles (MVs) and apoptotic bodies (ABs) appear to have a role in apoptosis-induced 
vascular calcification: ABs are calcium-enriched membrane-bound vesicles ~ 0.3 to 1.0 µm in 
diameter released from apoptotic VSMCs, MVs are smaller (30 to 300 nm) and may be 
remnants of apoptotic cells (91, 93, 94). For example, in advanced carotid artery 
atherosclerotic plaques, Kockx et al (92) found that the matrix vesicles were derived from 
VSMCs and contained the pro-apoptotic protein BAX (BCL2-associated X protein).  
Evidences support the role of apoptosis in calcification: some studies demonstrated that 
VSMC apoptosis occurs before the onset of calcification, and that inhibition of apoptosis 
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leads to a significant decrease in calcification (36). Proudfoot et al. reported that, in a human 
vascular calcification model, apoptosis occurred before the onset of calcification, and they 
demonstrated that inhibiting apoptosis also inhibits calcification, and stimulating apoptosis 
increases calcification. Apoptotic bodies derived from VSMCs may act as nucleating 
structures for calcium crystal formation (36). In 2008, Shanahan et al. demonstrated that 
dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell 
apoptosis: in the normal vessel wall, VSMCs were morphologically contractile, there was no 
evidence of extracellular vesicles, and the nuclei showed normal appearance and 
distribution of heterochromatin (93); however, VSMCs in dialysis vessels showed apoptosis 
and damage characterized by increased electron density of nuclear heterochromatin, cell 
shrinkage, and/or vesicle release. In this study, they hypothesize that Ca++ accumulation in 
the vessel begins in response to increased Ca++ and P, but protective mechanisms such as 
adequate mineralization inhibitor levels and extrusion of intracellular Ca++ via vesicle release 
preserves normal VSMC function. In the dialysis milieu, uremic toxins and the continued 
exposure to high Pi lead to apoptosis. This, in turn, increases local Ca++ levels and reduces 
local levels of VSMC-derived mineralization inhibitors, which potentiates osteo/chondocytic 
differentiation of smooth muscle cells and the release of pro-calcific vesicles that form a 
nidus for calcification (36).  
However, Giachelli et al (86) found that calcification of VSMCs does not appear to require 
apoptosis for the initiation of calcification: nonetheless, apoptosis appears to accelerate the 
calcification process once calcium phosphate crystals are deposited in the matrix. It has been 
demonstrated that both synthetic and human atherosclerosis-derived calcium phosphate 
crystals are phagocytosed by VSMCs, resulting in a rapid rise in intracellular calcium 
concentrations and resultant inflammation and cell death (73, 95). These effects were 
inhibited by the lysosomal proton pump inhibitor, bafilomycin A1 (73). 
How increased phosphorus concentrations result in apoptosis is unclear, but this process 
may be related to disruptions in normal mitochondrial energy metabolism (96). 
Mitochondria, in addition to supplying cellular energy, play a central role in the intrinsic 
apoptotic pathway. Mitochondria-mediated apoptosis involves the release of cytochrome c 
from the inner membrane space to the cytosol, which in turn triggers the activation of 
caspase-9 and -3 cascades (97, 98). These apoptotic events are closely linked to 
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mitochondrial dysfunction, which exhibits changed mitochondrial membrane potential, 
increased oxidant generation as a result of the perturbation of electron transport chain 
reaction, and decreased intracellular ATP content because of oxidant-insulted low 
respiratory activity (99-101). Although the precise mechanisms for mitochondria mediated 
apoptosis remain to be elucidated, oxidative stress caused by endogenously and 
exogenously excessive oxidant insults and/or impaired oxidant defenses is generally believed 
to be key in both mitochondrial dysfunction and cellular apoptosis (102). Mitochondria-
targeted antioxidants could inhibit the peroxidation of mitochondrial components including 
cytochrome c and consequently block apoptosis (103, 104).  
Furthermore, recent studies demonstrated that the Pi-induced VSMC apoptosis and 
subsequent calcification are dependent on the down-regulation of the Gas6/Axl/Akt survival 
pathway, that inhibits apoptosis and increases survival of VSMCs (35, 105). In fact, Son et al. 
demonstrated that the expression of Gas6 and Axl is markedly down-regulated in Pi-induced 
VSMC calcification. For instance, 3-hydroxy-3-methylglutaryl CoA reductase inhibitors 
(statins) protect VSMCs from Pi-induced calcification by suppressing apoptosis via 
restoration of Gas6/Axl/Akt survival pathway (35). They examined the role of Gas6-Axl 
interaction in the processes of apoptosis and calcification: they demonstrated that the 
addition of recombinant human Gas6 (rhGas6) to human VSMCs in vitro significantly 
inhibited both Pi-induced apoptosis and calcification. Furthermore, addition of Axl-
extracellular domain to block the binding of Gas6 to Axl clearly abrogated the inhibitory 
effect of Gas6 (35). Consistent with a study by Lee et al. (106), the pro-survival 
phosphorylation of Akt was down-regulated by Pi, and rhGas6 abrogated the decrease. 
Wortmannin, a specific PI3K inhibitor, abolished the rhGas6-induced phosphorylation of Akt 
and further eliminated the inhibitory effect of Gas6 on Pi-induced apoptosis and calcification 
(106). These findings indicate that the preventive effect of Gas6 on Pi-induced apoptosis and 
calcification is mediated by the PI3K-Akt pathway. It is well established that PI3K-Akt affects 
cell death through the Bcl2 family, critical regulators of apoptosis (106). In VSMC 
calcification, Pi inactivated Bcl2 and activated Bad, followed by caspase-3 activation, finally 
leading to apoptosis. 
There could be a close interplay between phosphate-induced VSMC phenotype change and 
apoptosis, as proposed recently by Shanahan’s group (107): VSMCs that adapt to the hostile 
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conditions by undergoing lineage reprogramming from contractile to synthetic bone forming 
phenotype are able to secrete matrix vesicles, thus avoiding calcium overload. In contrast, 
VSMCs that fail to differentiate succumb to apoptosis, which also results in budding of 
vesicles and matrix mineralization. Both pathways lead to extracellular calcium phosphate 
deposition with increased  risk of apoptosis of surviving VSMCs (95). 
 
2.6.3 Phosphate and autophagy in VSMCs 
Autophagy seems to be involved in VSMC vascular mineralization. The term ‘autophagic cell 
death’ has been widely employed to indicate a type of cell death that is accompanied by 
massive vacuolization of the cytoplasm (108). However, the relationship between autophagy 
and cell death remains controversial. In vivo studies on Drosophila melanogaster have 
provided evidences that cell death can be, at least partially, executed through autophagy 
(109-112) and, consistent with these results, the knockout/knockdown of essential 
autophagy genes has been shown to protect cultured mammalian cells from some lethal 
inducers (113). Nonetheless, more frequently, pharmacological and genetic inhibition of 
autophagy doesn’t prevent cell death, and, rather, accelerates it (114, 115). This evidences 
suggest that, although cell death can occur together with autophagy, the latter likely 
represents a pro-survival mechanism activated by dying cells in the attempt to cope with 
stress (114, 115). 
Autophagy is a dynamic and highly regulated process of self-digestion. It is a highly 
conserved cellular process responsible for removal or recycling of long-lived proteins and 
organelles, and it provides cells with an alternative source of nutrients from the reuse of 
cellular proteins and organelles. This lysosomal degradation pathway is essential for cell 
survival, differentiation and development, as well as the cellular response to stress. Limited 
autophagy in response to nutrient starvation has a survival function, and specific removal of 
damaged mitochondria by autophagy can prevent the activation of apoptotic pathways. 
Dai et al. demonstrated that, although the inhibition of autophagy reduced phosphate-
induced VSMC apoptosis, it caused an increment in calcium deposition in both animal 
(bovine and rat VSMCs) and human aortic cells. Moreover, their results shown that the 
induction of autophagy is correlated with a decrease of calcification in bovine VSMCs and rat 
aortic rings. So, autophagy could be an endogenous protective mechanism counteracting 
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phosphate-induced vascular calcification not acting by the decrease of VSMC apoptosis, but 
acting by the reduction of matrix vesicle release (116). 
 
2.7 Potential role of the sodium-dependent phosphate cotransporter Pit-1 in vascular 
calcification 
Phosphate transport into cells is primarily mediated by sodium-dependent phosphate 
cotransporters, and three types of cotransporters have been identified based on structure, 
tissues expression and biochemical characteristics (18, 117, 118) The type I and type II 
sodium-dependent phosphate cotransporters are primarily expressed in kidney and 
intestinal epithelium, and their functions are important for the maintenance of phosphate 
homeostasis in the body (117, 118). The type III sodium-dependent phosphate 
cotransporters, Pit-1 and Pit-2, were originally identified as cell surface receptors for the 
gibbon ape leukemia virus (Glvr-1) and the amphotropic murine retrovirus (Ram-1), 
respectively. Type III members are widely distributed in kidney, liver, lung, heart, brain, 
osteoblasts, chondrocytes and VSMCs (84, 87). 
A functional sodium-dependent phosphate transport system has been characterized in 
VSMCs (84, 87). RT-PCR revealed expression of type III sodium-dependent phosphate 
cotransporters, Pit-1 and Pit-2, while no transcripts for type I and type II sodium-dependent 
phosphate cotransporters were detected. Real-time PCR indicated that Pit-1 mRNA levels 
were higher than Pit-2 (84). Treatment of VSMCs with a competitive inhibitor of sodium-
dependent phosphate cotransporters, phosphonoformic acid (PFA), caused a dose-
dependent inhibition of phosphate uptake, calcification, and osteochondrogenic phenotype 
in VSMCs (87, 119). These results suggest that phosphate transporter activity is necessary for 
mineralization as well as osteochondrogenic transition in human VSMCs. 
Since PFA has lower affinity for type III than for type II receptors (120), the requirement of 
phosphate uptake for VSMC calcification was further examined using VSMCs that were 
stably transduced with Pit-1 specific small hairpin RNA (shRNA) (84). Pit-1 shRNA expressing 
cells had reduced mRNA and protein levels of Pit-1 as detected by Northern and Western 
blots, respectively. Sodium-dependent phosphate uptake in the cells was reduced compared 
to that in control cells. After incubation with elevated phosphate for 7, 10 or 14 days, there 
was substantially reduced calcification in Pit-1 knockdown cells compared to control cells. Of 
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interest, restoration of phosphate uptake in Pit-1 knockdown cells by over-expression of 
mouse Pit-1 rescued elevated phosphate-induced mineralization. Similar to PFA, inhibition of 
phosphate uptake by Pit-1 shRNA blocked the expression of phosphate-induced osteogenic 
differentiation markers, Runx2 and osteopontin. These studies indicated that sodium 
dependent phosphate cotransporters, in particular Pit-1, might be a major mechanism for 
controlling vascular calcification and VSMC phenotypic state. Taken together, these results 
demonstrate that phosphate transport via Pit-1 is required for calcification in cultured 
VSMCs.  
Recent studies have supported a role for increased phosphate uptake via Pit-1 in vascular 
calcification in vivo. Mizobuchi et al showed that mRNA levels of Pit-1 and Runx2 were 
increased in calcified aorta of uremic rats with severe hyperparathyroidism, while no 
increase was observed in non-calcified aorta of control animals (121). Likewise, LDLR−/− 
mice fed with a high-fat diet showed elevated levels of serum tumor necrosis factor α (TNF-
α) and Pit-1 in calcified aortic calcification. In vitro, several factors that have been shown to 
induce vascular calcification also induce Pit-1 in VSMCs. Long-term treatment of human 
VSMCs with elevated calcium levels leads to increased Pit-1 mRNA levels, phosphate uptake 
and calcification (122). Likewise, PDGF promotes calcification in cultured SMCs and strongly 
induces Pit-1 expression (90). In addition, bone morphogenetic protein 2 (BMP-2), a potent 
osteogenic protein, has been shown to promote vascular calcification (24, 41, 123) 
increasing phosphate uptake in a time-and dose-dependent manner (124). Interestingly, 
BMP-2 also promoted mineralization and upregulated Pit-1 expression in osteoblasts, and 
BMP2-enhanced mineralization in these cells was abrogated by Pit-1 siRNA (125). Finally, 
transglutaminase (TG) appears to be an important regulator of Pit-1 endogenous expression, 
since Pit1 levels were observed in TG+/+ SMCs but absent in TG−/− SMCs in the presence or 
absence of elevated phosphate (126).  
Thus, it is likely that phosphate transport via Pit-1 is a common requirement for cell-
mediated biomineralization (18). 
 
2.8 Calcium phosphate nanocrystals promote VSMC osteogenic gene expression 
Despite a plethora of studies addressing multiple aspects of P-induced calcification, results 
from different models and systems have often provided conflicting data, casting doubt on 
27 
 
the notion that uptake of P alone, acting via these signaling pathways, is all that is required 
to promote calcification. Also the presence of nanocrystalline Ca/P could lead to a 
pathological positive-feedback loop causing cell death, inflammation, phenotypic change, 
matrix degradation and calcification (79). 
The size of crystals is important in determining their effects on target cells (73): Ca/P crystals 
in the range of 1 -2 µm or less in diameter were endocytosed, caused  toxic  effects  in  
VSMCs  and induced the release of proinflammatory cytokines  from  macrophages,  whereas 
crystals  with  a diameter greater than 20 µm are mostly inert. This is possibly due to lack of 
cellular uptake of  these larger particles, which may be dissolved by alternate extracellular 
mechanisms that do not induce the same phenotypic effects as nanocrystal uptake (127). 
This implies that calcification is damaging in its earliest stages, prior to crystal growth or 
aggregation, making this initial stage the most important target for prevention. 
The study by Sage et al. highlights an important and novel role for calcium phosphate 
nanocrystals produced in a high-phosphate environment. Importantly, the presence of these 
crystals led to an increased expression of the osteogenic proteins BMP-2 and osteopontin in 
VSMCs, proteins that were not upregulated by high P alone (25). 
VSMCs undergo both apoptosis and phenotypic change at sites of calcification. In  
combination, all  these factors appear to  be  required  for  the deposition of Ca/ P 
nanocrystals in the vessel wall. 
 
2.9 Therapeutic strategies for vascular calcification treatment 
Relatively new pharmacological agents are used either alone, or in combination, to minimize 
hyperphosphatemia and hyperparathyroidism associated complications to improve 
morbidity and mortality of CKD patients (128). 
With time, new formulations of phosphorus binders have been developed to minimize side 
effects. For instance, once widely used aluminum-based phosphorus binders can induce 
anemia, myopathies, dementia and bone anomalies. Calcium-based binders, though 
somewhat effective, are also linked to vascular calcification in patients undergoing 
hemodialysis treatment (128). Recently, sevelamer carbonate, a non-calcium and non-
aluminum-based binder have been shown to reduce vascular injury better than calcium-
based binders (129, 130).  
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Another phosphate-binding agent used to reduce the gastrointestinal absorption of 
phosphate and ameliorate vascular calcification in advanced CKD is lanthanum carbonate 
(131). It has been extensively investigated in preclinical and clinical studies, demonstrating 
good efficacy in reducing serum phosphate levels, without major side effects, over 6 years of 
treatment (132). 
Additionally, cationic lanthanum (La+++), primarily based on its similarity to Ca++, can activate 
Calcim Sensing Receptor (CaSR), that is expressed in all the organs and cells that maintain 
systemic Ca++ (131). 
Even calcimimetics, such as cinacalcet and calindol, are positive allosteric modulators of the 
CaSR, interacting with the membrane-spanning domain of the receptor to induce a 
conformational  change  that  enhances  signal  transduction.  This change in conformation 
leads to increased sensitivity to extracellular  calcium  and  subsequently  to  a  decrease  in 
circulating PTH levels. Besides changing the structural conformation, calcimimetics can also 
enhance CaSR function by increasing its expression (133). 
 
2.9.1 Calcium sensing receptor (CaSR) and vascular calcification 
The consequence of the activation of the CaR and the cascade of intracellular signals the  
reduction in serum calcium concentration through the increase of urinary calcium excretion, 
the decrease of  bone  turnover,  and  the decrease of intestinal absorption of calcium. 
Noteworthy, studies have demonstrates that the expression of CaSR is reduced in human 
calcified arteries and in mineralized VSMCs, suggesting that it could play a preventive role in 
vascular mineralization when  expressed  normally, and that a functional CaSR is necessary 
to maintain a VMSC phenotype. 
Additional,  in  vitro  studies  have  also  demonstrated  that calcimimetics decrease 
calciﬁcation of human smooth muscle cells when cultured in high-phosphate medium; this 
inhibitory effect  is  abolished  by  the  transfection  in  these cells of a silencing CaSR RNA 
(SiRNA-CaR), suggesting that the direct activation of the CaSR in vascular cells may slowdown 
the calciﬁcation process. Calcimimetics may also prevent vascular calciﬁcation by modulating 
the expression of several genes involved in bone mineralization: they up-regulate  MGP  and  
down-regulate PiT1. Moreover, they are able to decrease the vascular expression of bone 
morphogenic protein-2, obstructing the osteoblastic transdifferentiation of VSMCs. The 
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activation of the CaSR by calcimimetics could also favor the regression of vascular 
calciﬁcation through the stimulation of macrophages or phagocytic cells adjacent to calciﬁed 
aortic lesions as found in an in vivo model of 5/6th nephrectomized rats. 
Altogether, the results of these in vitro and in vivo studies point toward a direct implication 
of the CaSR in the mechanisms of vascular function and mineralization (133). 
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3. AIM OF THE STUDY 
 
Since more than 90% of CKD patients dies for cardiovascular events and the main uremic 
toxin involved in cardiovascular calcification is high phosphorous, we decided to develop an 
in vitro model to elucidate the molecular and cellular mechanisms involved in the 
pathogenesis of vascular calcification.  
In particular, we studied this pathological process in VSMCs challenged for 7-15 days with 
high Pi (inorganic phosphorous). Our model has the purpose to reproduce in vitro the same 
pathological process that occurs in CKD patients in vivo. 
Known the ability of VSMCs to remodel their phenotypic characteristics in response to 
environmental changes and known the primary role of high phosphorous on vascular 
calcification and on osteoblastic differentiation of VSMCs, the main purpose of our in vitro 
studies was to develop potential strategies that allow VSMCs to contrast the progression of 
high Pi-induced calcium deposition.  
 
In the first part of these studies, we tried to better elucidate the role of the pleiotropic 
protein osteonectin (SPARC) in the process of vascular calcification, because, currently, the 
studies about the modulation of this protein expression in vascular calcification are few and 
controversial. Therefore, our purpose was to investigate its role in our model of vascular 
calcification in vitro and ex-vivo. 
 
In the second part of the project, we investigated the potential effect of repeated and short 
time suspensions of high Pi treatment (process that we called “Wash Out”) on the 
progression of calcium deposition in vitro, trying to reproduce the same temporal decrease 
of Pi levels that occurs in CKD patients treated with haemodialysis three times weekly. 
Moreover, our purpose was to investigate which are the high Pi induced molecular pathways 
responsible for the pathological calcium deposition in the vasculature that could be 
potentially modulated by the “Wash Out” treatment.  
 
The third part of the project is a pharmacological study that has the intention to investigate 
the mechanism of action of Lanthanum Chloride (LaCl3), Gadolinium Chloride (GdCl3) and  
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Calindol on the delay of the progression of high Pi-induced calcium deposition and on the 
osteoblastic transformation of VSMCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
4. MATERIALS  
 
DMEM (high glucose, [4,5 g/l]), NaCl, FBS and BCA protein assay kit (Pierce) were purchased 
from Euroclone (Milan, Italy); Na3PO4, MgSO4, NaH2PO4, KH2PO4 and KCl were from Carlo 
Erba (Milan, Italy); CaCl2 was from BDH (Bristol, England); calcium kit was from Pokler Italia 
(Salerno, Italy); primary antibody for α-actin (A2547) and anti-mouse secondary antibody 
(A9917) were from Sigma (St.Louis, MO, USA); primary antibody for SM22α (ab10135) and 
anti-goat secondary antibody (ab6741) were from Abcam (Cambrige, UK); primary antibody 
for Axl (sc-1097) and Calindol hydrochloride were from Santa Cruz (Heidelberg, Germany); 
primary antibody for LC3-II was from Cell Signalling (Danvers, USA) and anti-rabbit secondary 
antibody was from GeneTex (Irvine, USA); primary antibody for osteonectin (N50) was from 
Biodesign International (Saco, ME, USA); primary antibody for Ki67 (mib1) was from Dako 
(Glostrup, Denmark); Hepes Buffer Solution, PVDF membrane, Taqman gene assay for 
Cbfα1/RUNX2 (Rn_01512298), BMP-2 (Rn_00567818), MGP (Rn_00563463) and α-actin 
(Rn_00667869) and all reagents for gene expression assays were from Invitrogen/Applied 
Biosystem (Milan, Italy); PFA was from Fluka; cell-death detection ELISA plus Kit was from 
Roche. Unless otherwise mentioned, all the other reagents were obtained from Sigma 
(St.Louis, MO, USA). 
 
5. METHODS 
  
5.1 Induction of calcification in VSMC in vitro model 
Male Sprague-Dawley rats were killed by intraperitoneal injection of an overdose of sodium 
pentobarbital (150 mg/kg), and this protocol fully complied with recommendations in the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals.  
Rat VSMCs were obtained by enzymatic digestion and they were routinely sub-cultured in 
growth medium (DMEM containing 10% FBS supplemented with 100U/ml penicillin, 
0.1mg/ml streptomycin). At 80% confluence, cells were switched to calcification medium 
(DMEM containing 12% or 15% FBS supplemented with 100U/ml penicillin, 0.1mg/ml 
streptomycin, 10mM sodium pyruvate and the pro-calcific factors 5mM Pi and 50μg/ml 
ascorbic acid) for up to 15 days.  
Medium was replaced every 2 or 3 days.  
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For time-course experiments, the first day of culture in calcification medium was defined as 
day 0. 
 
 In “Wash Out” experiments, we define “Wash Out” treatment the temporary 
suspension of high Pi every time medium was replaced: in particular, 5mM Pi 
treatment was suspended for 2 or 4 hours every time medium was replaced to be, 
then, added again after the “Wash Out” period. 
 In the pharmachological study, LaCl3, GdCl3 and Calindol were added 2 hours before 
the addiction of high Pi every time medium was replaced.  
 
 
Cells were used between the sixth and eight passage, and calcium deposition was quantified 
using two alternative approaches, o-cresophtalein method and Alizarin Red S staining 
followed by HClO4 destaining and spettrophotometrical determination.  
Ca++ deposition of the cell layer was normalized to protein content and expressed as μg 
Ca++/mg protein or as absorbance (OD)/mg protein.  
 
5.2 Quantification of calcium deposition in VSMCs 
For the quantification of calcium deposition, we utilized two alternative approaches: o-
cresophtalein method and Alizarin Red S staining followed by HClO4 destaining.  
For the former method, cells were decalcified by incubation for 24 hours with 0.6 M HCl, and 
Ca++ content in HCl supernatants was determined colorimetrically at 575nm wavelength by 
the ο-cresophthalein complexone method.  
For the latter, extracellular calcium deposits were stained with Alizarin Red S solution for 30 
minutes to be, then, destained for 24 hours with 5% perchloric acid, and Ca++ content in 
HClO4 supernatants was determined colorimetrically at 450nm wavelength.  
After decalcification, cells were washed three times with PBS and solubilized with 0.1 N 
NaOH/0.1% SDS. Protein content was quantified by BCA protein assay kit (Pierce), and Ca++ 
deposition of the cell layer was normalized to protein content and expressed as μg Ca++/mg 
protein or as absorbance (OD)/mg protein.  
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5.3 Alizarin Red, Von Kossa and Immunohistochemistry 
To visualize calcium deposition, cells were grown on plastic supports and, at the end of the 
experiment, they were fixed with 70% EtOH and stained with 1mg/ml Alizarin Red S solution 
for 30 minutes. Cells were rinsed and Ca++ deposition was photographed.  
Besides rat VSMCs, we analyzed human arteries ex vivo by isolating, during autoptic 
examination, aortic walls from a fetus at 20th gestation weeks, a 35 years old young adult 
with hypertension, but without macroscopically evident arteries injury and two over 65 
years old adults with and without calcified atheromatous plaques.  
For Von Kossa and immunohistochemistry analysis, cell cultures and arteries were fixed in 
formalin and paraffin embedded, and 3 μm sections were stained.  
Von Kossa tissue staining was performed incubating slides with a 5% silver nitrate solution 
reduced under UV lamp for 1 hour, then, after 2-3 minutes in 5% sodium thiosulfate 
solution, were counterstained with safranine. Calcium deposits were visualized as black 
metallic silver granules. The deposition of calcium salts by Von Kossa staining was evaluated 
as the presence of fine granules or large calcific deposits. Cultured cells evaluation focused 
on the presence or absence of the same, on their arrangement (small or large aggregates), 
and on the morphology (round or spindle). 
Alizarin Red and Von Kossa expression were evaluated with a semi quantitative method, 
using a score system (0-4) related to the stained area (0 < 10%; 1 = 11-25%; 2 = 26-50%; 3 = 
51-75%; 4 > 75%).  
The evaluation of osteonectin protein was performed using monoclonal antibody to 
osteonectin (1:30,000), while cell proliferation with monoclonal antibody to Ki67 (1:100) 
incubated 1 hour at RT. For immunohistochemistry stain, Biogenex i6000 Automated 
Staining System (Biogenex, freemont, CA, USA) was used. The reaction was detected by 
Novolink Max polymer detection system (Novocastra Laboratories L.T.D., Leica 
Microsystem), following the manufacturer’s instructions, using as chromogen 
Diaminobenzidine (DAB), incubated for 8 minutes at RT. 
Osteonectin expression was assessed with semi-quantitative methods: 
1) Percentage of positive cells was related to the stained area: 0 ≤ 10%; 1 = 11-25%; 2 = 
26-50%; 3 = 51-75%; 4 > 75%. 
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2) Staining intensity was scored: 0 = absence of positive cells; 1 = positive cells with 
weak intensity; 2 = positive cells with intermediate intensity and 3 = positive cells 
with high intensity. 
3) Cellular distribution was scored: 1 = para-nuclear; 2 = cytoplasmic and membranous 
diffuse. 
Proliferation index (Ki-67) was determined counting positive cells on 100 VSMC at 
high magnification (40x). Ki-67 was reported as percentage with a semi-quantitative 
score: 0 = 0; 1 ≤ 10%; 2 = 11-25%; 3 = 26-50%; 4 = 51-75%. When 100 cells were not 
available, stained cells on total available cells were related to 100.  
 
5.4 Electron microscopy in VSMCs 
Samples of cells were scraped from culture flask, fixed in 2.5% glutaraldehyde in 0.13M 
phosphate buffer pH 7.2-7.4 for 2 hours, post-fixed in 1% osmium tetroxide, dehydrated 
through graded ethanol and propylen oxide and embedded in epoxy resin. Ultrathin sections 
were counterstained with uranyl acetate and lead citrate, to be observed in a Jeol JEM 1010 
transmission electron microscope (Jeol, Tokyo, Japan). 
 
5.5 RNA extraction and Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Total RNA was extracted using PureLink RNA Mini Kit according to the manufacturer's 
instructions. The concentration of RNA was measured using a UV spectrophotometer. 
Reverse transcription was performed with high capacity RNA-to-cDNA kit. All TaqMan PCR 
was performed using a StepOne Real-Time PCR System. Each reaction mixture (20μl) 
contained 10μl of 2X TaqMan Universal PCR Master Mix, 1μl of Taqman gene assay, 9μl of 
cDNA sample [(4ng (MGP), 50ng (Cbfα1/RUNX2), or 100ng (BMP-2)] and water. The thermal 
cycling conditions comprised the initial steps at 95°C for 10 minutes followed by 40 cycles at 
95°C for 15 seconds and at 60°C for 1 minute. Amplification of the target genes was 
normalized to simultaneous amplification of an internal housekeeping gene, β-actin, and 
calibrated to a low expressing, normalized, target sample. 
 
5.6 Western Blot  
Rat VSMCs were harvested in ice-cold homogenization buffer (50mM Tris pH 8 with 0.5% 
IGEPAL CA-630, 1mM phenylmethanesulfonyl fluoride (PMSF), 1mM benzamidine HCl, 1mM 
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sodium fluoride (NaF), 10mM β-glycerophosphate and complete protease inhibitor), freeze-
thawed 2X and sonicated 5 x 20 s at 40% power. Samples were then centrifuged at 13,000 g 
for 15 minutes at 4°C, and protein concentration was measured. Denatured samples (5, 1 or 
50 μg total protein for α-actin, SM22α and Axl and LC3-II, respectively) were separated by 
electrophoresis on a 12% (α-actin, SM22α and LC3-II) or 7.5% (Axl) SDS-polyacrylamide gel 
and, then, were transferred to PVDF membrane. Membranes were incubated 1 hour with 
1:7,500 (α-actin) or 1:2,500 (SM22α), or O/N with 1:200 (Axl) or 1:300 (LC3-II) primary 
antibodies, followed by 1 hour incubation with 1:40000 (α-actin) peroxidase-conjugated 
anti-mouse, 1:5,000 (SM22α) or 1:10,000 (Axl) peroxidase-conjugated anti-goat or 1:20,000 
(LC3-II) peroxidase-conjugated anti-rabbit secondary antibodies. Protein bands were 
visualized using an ECL detection kit, and area intensity was measured. 
For the analysis of LC3-II marker, some cells were pre-incubated O/N  at 37°C with 25μM 
chloroquine the day before sample harvest. 
 
5.7 Detection of apoptosis  
Cytoplasmic histone-associated DNA fragments were detected with a cell-death detection 
ELISA plus kit as a quantitative index of apoptosis. Briefly, after VSMCs were scraped in lysis 
buffer and sonicated 5 x 20 s at 40% power, samples were centrifuged at 200 x g for 10 min 
at RT, and 20μL of supernatant (cytoplasmic fraction) was used for the assay. Following the 
addition of substrate, colorimetric change was determined by the absorbance value 
measured at 405nm. 
 
5.8 Short time Phosphonoformic Acid (PFA) treatment in the “Wash Out” model 
VSMCs were exposed for 4 hours to 1mM  phosphonoformic acid (PFA) in presence of 5mM 
Pi every time medium was replaced. In the attempt to limit PFA effect on the 4 hours 
treatment, VSMCs were washed with PBS after this period of incubation, and calcification 
medium with 5mM Pi was added, again. Calcium deposition was quantified using Alizarin 
Red S staining followed by HClO4 destaining and spettrophotometrical determination. 
Absorbance values were normalized by protein content. 
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5.9 Strategies to study the contribution of active and passive components on vascular 
calcification in the “Wash Out” model 
 
5.9.1 Short time “Wash Out” samples exposition to “choline-saline solution”  
VSMCs were exposed to “choline-saline solution” (1M Hepes Buffer Solution, 25mM D-
glucose, 140 mM Choline-Cl, 0.8 mM MgSO4, 0.9 mM KH2PO4, 5.36 mM KCl, 1.8 mM CaCl2) or 
they were treated with the same saline solution with Na+ instead of choline (“Na+-saline 
solution”, with 140mM NaCl and 0.9mM NaH2PO4 rather than Choline-Cl and KH2PO4) in 
presence of 5mM Pi for 2 hours every time medium was replaced. 
Calcium deposition was quantified using Alizarin Red S staining followed by HClO4 destaining 
and spettrophotometrical determination. Absorbance values were normalized by protein 
content. 
 
5.9.2 Short time targeted PFA treatment in “Wash Out” samples 
Calcification medium cell-free was pre-incubated with 5mM Pi, at 37°C O/N the day before 
the replacement of medium to allow the precipitation of hydroxyapatite crystals in absence 
of cells. VSMCs were exposed to this pre-incubated medium in the presence of 1mM PFA for 
4 hours every time medium was replaced. Then, cells were washed with PBS and calcification 
medium was added, again, in presence of 5mM Pi. 
Calcium deposition was quantified using Alizarin Red S staining followed by HClO4 destaining 
and spettrophotometrical determination. Absorbance values were normalized by protein 
content. 
 
5.9.3 Short time free Pi and calcium-phosphate crystals treatment in “Wash Out” samples 
Calcification medium cell-free was pre-incubated with 5mM Pi, at 37°C O/N the day before 
the replacement of medium to allow the precipitation of hydroxyapatite crystals in absence 
of cells. Medium was repeatedly centrifuged at 16,000 x g for 5 min at RT in order to allow 
the isolation of hydroxyapatite crystals (precipitate) from free Pi (supernatant). VSMCs were 
exposed to hydroxyapatite crystals or free Pi for 4 hours every time medium was replaced, 
then they were washed with PBS, and calcification medium was added, again, in presence of 
5mM Pi. 
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Calcium deposition was quantified using Alizarin Red S staining followed by HClO4 destaining 
and spettrophotometrical determination. Absorbance values were normalized by protein 
content. 
 
5.10 Statistical analysis 
Results were expressed as mean ± SEM. Each experiment was performed at least three times 
at least in triplicate. Differences between groups were analyzed by one-way ANOVA and are 
considered statistically significant when p value < 0.05. 
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6. RESULTS  
 
6.1 MODULATION OF OSTEONECTIN EXPRESSION IN VASCULAR CALCIFICATION 
PATHOGENESIS 
 
6.1.1 Effect of high Pi on VSMCs 
VSMCs challenged with 5mM Pi for 7 days calcify. To demonstrate the ability of these cells to 
deposit calcium, we decided to investigate ultra-structural changes high Pi induced using 
electron microscoscopy. In high Pi treated VSMCs there are calcified mitochondria, 
numerous electron dense calcium deposits, mainly in the extracellular matrix near plasma 
membrane, and there is an extracellular vesicles trafficking (Fig. 1B, C). On the contrary, no 
calcium deposits and no ultra-structural changes were seen in control samples (Fig 1A). 
 
 
 
Figure 1: Effects of high phosphate on VSMCs showed by electron microscopy 
A: Control VSMCs; B-C: 5mMPi.  
B C 
A 
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A: Ultra-structural integrity of normal cells, that have the characteristic morphology of VSMCs. 2,500x original 
magnification B: Electron micrograph showing calcium electron dense deposits in extracellular matrix between 
neighboring cells (arrows). 2,500x original magnification; B: Particular of a cytoplasmic process with calcium 
deposits close to cell membrane. 10,000x original magnification. Inset: Higher magnification of the boxed area 
showing the remnant of an exocytosis vesicle on membrane near a calcium deposit. 
 
6.1.2 Effect of high Pi on the modulation of VSMC Osteonectin expression 
In order to elucidate the potential role of osteonectin in vascular calcification, we evaluated 
high Pi-induced osteonectin expression time-course in our in vitro model from a histological 
point of view analysing three different parameters: percentage of positive cells, staining 
intensity, and cellular distribution of the staining. In the time course, three different points 
have been evaluated: 2, 4, and 7 days of high-Pi treatment. 
In controls, at every day tested, osteonectin was present in few VSMCs (score 0), with a faint 
staining (score 0-1), in paranuclear position (score 1), specifically at 7 days (Fig. 2A).  
Under calcification stimuli, after 4 days of challenge, all the parameters in osteonectin 
staining did not increase significantly (score 1 in expression, intensity, and subcellular 
position) (Fig. 2B). On the contrary, at 7 days large amount of cells express diffusely 
osteonectin (score 4) in the cytoplasm (score 2), with stronger intensity (score 3) (Fig 2C). At 
day 2, osteonectin staining pattern is not different from control cells, and, after 10 days of 
high-Pi challenge, there are not differences compared to day 7, with a dispersion of 
osteonectin from cells toward cellular matrix due to the lost of cells vitality (data not 
shown). 
 
 
Figure 2: Time course of osteonectin protein expression in high Pi condition 
VSMCs were cultured in calcification medium with 5mM Pi, and osteonectin protein expression was measured 
by immunohistochemistry. Time course shows that 7 days after high Pi challenge there is a significant increase 
in osteonectin protein levels. A: Control VSMCs: osteonectin staining was present in few cells (score 0), with a 
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faint staining (score 0-1), in paranuclear position (score 1); B: 5mM Pi, day 4: osteonectin staining was present 
in some cells (score 1), with a faint staining (score 1), in paranuclear position (score 1); C: 5mM Pi, day 7: large 
amount of cells express diffusely osteonectin (score 4), with strong intensity (score 3), in the cytoplasm (score 
2). Magnification x20. Representative result of one of three different experiments. 
 
To clarify the relationship between osteonectin and vascular calcification, we next analyzed 
calcium deposition time course with Von Kossa staining, that shows a pattern of expression 
according with osteonectin. 
Control cells do not accumulate calcium deposits (score 0) (Fig. 3A), whereas in VSMCs 
challenged with high Pi for 4 days there are some calcified deposits (score 1-2) (Fig. 3B), that 
become more and more apparent and consistent after 7 days of culture in calcification 
medium (score 2) (Fig. 3C), according to the expression of osteonectin. Started to day 10, 
calcification was more pronounced also due to cell death (data not shown). 
 
 
Figure 3: Time course of calcium deposition in high Pi condition 
VSMCs were cultured in calcification medium with 5mM Pi, and calcium deposition was measured by Von Kossa 
staining. Time course shows that 7 days after high Pi challenge there is a significant increase in calcium 
deposition. A: Control VSMCs: no calcium deposits were present in control cells (score 0); B: 5mM Pi, day 4: 
black stained calcium deposits were diffusely present between the cells (score 1-2). C: 5mM Pi, day 7: large 
black stained calcium deposits were massively present between the cells (score 2). 
Magnification x20. Representative result of one of three different experiments. 
 
 
6.1.3 Effect of high Pi on the modulation of VSMC Ki67 expression  
Since osteonectin is a protein produced in tissue that undergo remodeling and 
differentiation, in order to understand whether its expression correlated with cell 
proliferation in our model, we investigated, with an immunohistochemistry assay, the time 
course expression of Ki67, a nuclear marker of cellular proliferation.  
42 
 
In controls, at every time point tested, Ki-67 was present in very few cells (score 0) (Fig. 4A). 
After 4 days of high Pi challenge, the number of nuclei that stain for Ki-67 increased (score 2) 
(Fig. 4B), decreasing after 7 days (score 0) (Fig. 4C).  
 
 
 
Figure 4: Time course of Ki-67 protein expression in high Pi condition 
VSMCs were cultured in calcification medium with 5mM Pi, and Ki-67 protein expression was measured by 
immunohistochemistry. Time course shows that 4 days after high Pi challenge there is a significant increase in 
Ki-67 protein levels. A: Control VSMCs: in control condition few nuclei stain for Ki-67; B: 5mM Pi, day 4: some 
nuclei stain for Ki-67 (score 2); C: 5mM Pi, day 7: Ki-67 staining decrease at control level. 
Magnification x20. Representative result of one of three different experiments. 
 
6.1.4 Effect of high Pi on the modulation of VSMC Cbfα1/RUNX-2 expression  
As in our model osteonectin expression was not strictly related to proliferation, we tried to 
evaluate osteonectin association with the expression of the master gene involved in 
osteoblast differentiation, Cbfα1/RUNX-2, to elucidate if the time of the maximal VSMC 
transformation correlated with osteonectin expression. Cbfα1/RUNX2 is a transcription 
factor strongly expressed during the transition of VSMCs towards the osteoblastic-like 
phenotype when they are exposed to a pro-calcific environment. We investigated, with a 
real time PCR assay, the time course expression of Cbfα1/RUNX-2 in VSMCs challenged with 
5mM Pi up to day 9.   
For Cbfα1/RUNX-2, after 7 days of incubation, the challenge with 5mM Pi results in a peak 
with a 4.44 ± 0.74-fold increase in messenger RNA (mRNA) compared to the relative 
expression in normal VSMCs (t0) (*p < 0.01) (Fig. 5). 
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Figure 5: Time course of Cbfα1/RUNX-2 mRNA expression in high Pi condition 
VSMCs were cultured in calcification medium with 5mM Pi, and Cbfα1/RUNX2 mRNA expression was measured 
by RT-PCR. Time course shows that 7 days after high Pi challenge there is a significant increase in Cbfα1/RUNX2 
mRNA levels compared to the relative expression in normal VSMCs (t0).  
Data were presented as mean ± SE of three different experiments (*p < 0.01). 
 
6.1.5 Effect of Ascorbic Acid on the modulation of VSMC Osteonectin expression 
In order to elucidate the potential role of osteonectin in VSMC calcification, we tried to 
associate its expression with a factor that we previously demonstrated to be involved in the 
promotion of the calcification process (134): ascorbic acid (AA).  
Figure 6 demonstrates the pro-calcifying effect of AA: when removed from the calcification 
medium, the high Pi-induced calcification in absence of AA at day 7 decreases compared to 
the high Pi-induced calcification in presence of AA (32.5 ± 4.7 5mM Pi with AA vs 12.7 ± 0.8 
5mM Pi without AA; μg Ca++/mg protein; *p < 0.01). 
 
 
Figure 6: Effect of ascorbic acid on calcium deposition 
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VSMCs were cultured in calcification medium with 5mM Pi in presence (black bars) or in absence (gray bars) of 
AA for 7 days. Ca
++
 deposition was measured and normalized by cellular protein content. Removing AA from 
the calcification medium results in a significant decrease of Ca
++
 deposition. 
Data are presented as mean ± SE (*p < 0.01). 
 
 
Therefore, we studied osteonectin expression modulation by the presence or absence of AA 
and we chose to analyze its expression at day 7, the same time point of osteonectin 
expression peak.  
Results show that, removing AA from the calcification medium results in a decrease of 
osteonectin expression, with less cells that diffusely expressed it (score 4 vs 3; with or 
without AA) and with a less strong intensity (score 3 vs 2; with or without AA), but with the 
same cytoplasmic subcellular localization (Fig. 7A-B). 
 
 
Figure 7: Effect of ascorbic acid on osteonectin expression in high Pi conditions 
VSMCs were cultured in calcification medium with 5mM Pi in presence (A) or in absence (B) of AA for 7 days. 
Removing AA from the calcification medium results in a significant decrease in osteonectin expression 
A: Large amount of cells express diffusely osteonectin (score 4), with strong intensity (score 3), in the 
cytoplasm (score 2). B: Decrease of ostonectin expression with less cells that expressed diffusely osteonectin 
(score 3), with less strong intensity (score 2), in the cytoplasm (score 2). 
Magnification x20. Representative result of one of three different experiments. 
 
6.1.6 Effect of high Pi on the modulation of Osteonectin ex-vivo 
The observation that osteonectin was expressed in high Pi challenged VSMCs in vitro has 
suggested that it may be involved in the regulation of the osteo/chondrocytic transition of 
VSMCs in vivo, so we decided to study its expression ex-vivo in human arteries from a fetus, 
a 35 years old young adult with hypertension but without macroscopically evident arteries 
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injury, and from two over 65 years old adults without and with calcified atherosclerotic 
plaques.  
As shown in Figure 8, in human arteries osteonectin was localized, as expected, in VSMCs 
with a great intensity in fetal life. In the fetal artery, osteonectin has a strong staining (Fig. 
8A, and inset). The specimen from the 35 years old patient is an artery with regular 
architecture, with small signs of fibrosis due to hypertension, considerable as a normal 
human artery. Osteonectin staining is not very intense compared to the fetal artery (Fig. 8B, 
and inset). In the atheromatous plaque, both non calcific and calcific, where the muscular 
layer was displaced by fibrous tissue, osteonectin is present with strong immunoreactivity in 
residual muscular cells (Fig. 8C-D, and insets). 
 
 
Figure 8: Osteonectin expression in fetal, adult non calcific and adult calcific vessels 
A: Artery of a 20
th
 gestational weeks male fetus: strong and diffuse staining in the muscular wall of VSMCs; B: 
Artery from a 35 year old young adult with hypertension but without macroscopically evident artery injury: 
osteonectin staining is not very intense; C: Artery from a 65 year old adult without calcified atheromatous 
plaques: strong staining in residual VSMCs of aortic wall with atheromatous plaque; D: Artery from a 65 year 
old adult with calcified atheromatous plaques: strong staining in few residual VSMCs of aortic wall with 
calcified atheromatous plaque. A, B, C: original magnification 20X; D: original magnification 10X; inset: original 
magnification 40x. Representative result of one of three different experiments. 
 
 
In order to link osteonectin expression with calcium deposition, we evaluated Von Kossa 
staining on human arteries. No calcium deposits were present in muscular wall of a 20 weeks 
fetus (Fig. 9A) and 35 years old patient (Fig. 9B), but we were able to detect calcium 
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accumulation as fine deposits between the muscle layer of non-calcified atheromatous 
plaque (Fig. 9C, and inset), and large bulks in calcified plaque (Fig. 9D). 
 
 
Figure 9: Calcium deposition in embryonic, adult non-calcific and adult calcific vessels 
A: Artery of  a 20
th
 gestational weeks male fetus: no calcium deposits were present in the muscular wall; B: 
Artery from a 35 year old young adult with hypertension but without macroscopically evident artery injury: no 
calcium deposits were present in the muscular wall; C: Artery from a 65 year old adult without calcified 
atheromatous plaques: only very few small calcium granules were present in the muscular aortic wall; D: Artery 
from a 65 year old adult with calcified atheromatous plaques: black stained calcium deposits were present in 
muscular aortic wall with calcified atheromatous plaque. A, B, C, D: original magnification 4X; inset: original 
magnification 40X. Representative results of one of three experiments. 
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6.2 PROTECTIVE EFFECTS OF “WASH OUT” TREATMENT ON THE PROGRESSION OF VSMC 
HIGH Pi-INDUCED CALCIFICATION  
 
6.2.1 “Wash Out” effect on calcium deposition 
High Pi concentration (5mM) was able to induce VSMC calcium deposition.  
In “Wash Out” experiments, some cells were cultured in continuous presence of high Pi for 7 
days, others had a temporary short time suspension of high Pi challenge. Short and repeated 
high Pi suspension was able to induce an inhibition of calcium deposition in VSMCs, and this 
protective effect is dependent on the duration of high Pi treatment suspension, with a 
maximal inhibition when high Pi treatment was suspended for 4 hours (“Pi-4h” condition) 
every time medium was replaced (2 times in 7 days) (0.55 ± 0.02 ctrl;  0.675 ± 0.62 5mM Pi; 
603 ± 0.16 Pi-3h; 478 ± 0.19 Pi-4h; OD/mg protein; *p < 0.01, Fig. 10).  
Since 4 hours of high Pi suspension results in a higher inhibition of calcium deposition 
compared with the 3 hours suspension, in our study we decided to suspend the calcific 
stimulus for 4 hours every time medium was replaced. 
 
 
Figure 10: Effect of different time of high Pi suspension on calcium deposition 
VSMCs were cultured with 5mM Pi in the calcification medium for 7 days. The duration of high Pi suspension 
correlates with the inhibition of calcium deposition. Ca
++
 deposition was measured and normalized by cellular 
protein content. Data were presented as mean ± SE of four different experiments. Figure shows a 
representative experiment (*p < 0.01). 
 
In order to evaluate if the protective effect induced by “Wash Out” treatment was persistent 
during the progression of calcification, we investigated the effect of this treatment 10 days 
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after VSMC challenge, with the suspension of high Pi treatment every time medium was 
replaced (3 times in 10 days).  
Our results demonstrate that “Wash Out” significantly inhibits VSMC calcium deposition not 
only after 7, but, also, after 10 days of high Pi treatment (0.53 ± 0.06 ctrl;  97.42 ± 9.12 5mM 
Pi; 59.23 ± 5.18 Pi-4h, day 7 of calcification; 0.42 ± 0.03 ctrl;  131.66 ± 18.7 5mM Pi; 68.33 ± 
10.53 Pi-4h, day 10 of calcification; μg Ca++/mg protein; *p < 0.01) (Fig. 11).  
 
 
 
Figure 11: Effect of number of high Pi suspensions on inhibition of calcium deposition 
VSMCs were cultured with 5mM Pi in the calcification medium for 7 (A) or 10 (B) days, and high Pi treatment 
was suspended for 4 hours every time medium was replaced. There are no significant differences between the 
reduction of Ca
++
 deposition in “Wash Out” treatment stopped at day 7 compared to “Wash Out” treatment 
prolonged for 10 days. Ca
++
 deposition was measured and normalized by cellular protein content.  
Data were presented as mean ± SE of four different experiments (*p < 0.01). 
 
Challenging VSMCs with high Pi for 7 days results in calcium deposition, that is detectable by 
Alizarin Red staining. The positive staining present in high Pi samples was partially inhibited 
by “Wash Out” treatment (Fig. 12). The semiquantitative analysis confirms a significant 
decrease in calcium deposition in cells that received a 4 hours high Pi suspension every time 
medium was replaced (0 ctr, 3.0 ± 0.2 5 mM Pi and 1.2 ± 0.07 Pi-4h; score 0-4) (Fig. 12). 
 
 
 
 
 
 
*
 *
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Figure 12: Effect of “Wash Out” on calcium deposition 
VSMCs were cultured with 5mM Pi in the calcification medium for 7 days and high Pi treatment was suspended 
for 4 hours every time medium was replaced. Ca
++ 
deposition was assessed at light microscopic level by Alizarin 
Red staining. Control VSMCs (A), 5mM Pi (B) and Pi-4h (C). A: No deposit were found in the control culture; B: 
Red color indicates deposits of Ca
++
-containing mineral; C: Decrease in Ca
++
-containing mineral deposits due to 
the 4 hours highPi suspension. Magnification x200.  
Representative result of one of three different experiments. 
 
 
To study in detail the effect of “Wash Out” treatment on VSMC calcification, we next 
analyzed 4 hours high Pi suspension on calcium deposition after 9 days of culture in 
calcification, evaluating toluidine blue staining on semi-thin slides.  
Images show the presence of spreader and larger calcium deposits in VSMCs continuously 
exposed to high Pi compared to cells that received 4 hours suspension treatment every time 
medium was replaced, without calcium deposits in control samples, accordingly with alizarin 
red staining results (Fig. 13). 
 
 
Figure 13: Effect of “Wash Out” on calcium deposition analyzed in semi-thin sections   
VSMCs were cultured with 5mM Pi in the calcification medium for 9 days and high Pi treatment was suspended 
for 4 hours every time medium was replaced. Ca
++
 deposition was assessed level with Toluidine Blue staining. 
Control VSMCs (A), 5mM Pi (B) and Pi-4h (C). A: No deposits were found in the control culture; B: Dark blue 
color indicates Pi-dependent deposits of Ca
++
-containing mineral; C:  A decrease in Ca
++
-containing mineral 
deposits due to the 4 hours high Pi suspension.  
Representative result of one of three different experiments. 
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6.2.2 Effect of repeated short time PFA treatment on calcium deposition 
 
In order to demonstrate that the protective effect on calcium deposition obtained from 4 
hours “Wash Out” treatment is due to the short time absence of high-Pi pro-calcific action 
on VSMCs, we studied the response of short time phosphonoformic acid (PFA) treatment on 
calcium deposition in presence of the calcific stimulus 5mM Pi. PFA is a sodium-dependent 
phosphate co-transporter (Pit-1) and hydroxyapatite formation inhibitor.  
During 7 days of high Pi challenge, short and repeated 1mM PFA treatment of VSMCs 
constantly exposed to high Pi was able to delay the progression of vascular calcification: in 
VSMCs challenged for 4 hours with 1mM PFA treatment every time medium was replaced 
there is a significant inhibition of calcium deposition compared to cells continuously exposed 
to high Pi but not treated with PFA, and this inhibition is comparable with those resulted 
from “Wash Out” treatment (0.051 ± 0.002 ctrl; 0.787 ± 0.053 5mM Pi; 0.493 ± 0.033 Pi-4h; 
0.452 ± 0.038 5mM Pi + 1mM PFA 4h; OD/mg protein; *p < 0.01) (Fig. 14).  
 
  
Figure 14: Effect of PFA treatment during “Wash Out” period on calcium deposition 
VSMCs were cultured with 5mM Pi in the calcification medium for 7 days. Some cells were cultured in absence 
of high Pi for 4 hours every time medium was replaced, and others cells were treated with 1mM PFA for 4 
hours every time medium was replaced in continuous presence of high Pi. Ca
++
 deposition was measured and 
normalized by cellular protein content. 
Data were presented as mean ± SE of four different experiments (* p < 0.01). 
 
 
 
 
 
 
* * 
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6.2.3 Effect of repeated short time inhibition of phosphate entry in VSMCs on calcium 
deposition 
 
In the attempt to understand the relevance of the Pi influx in the “Wash Out” in vitro model, 
we studied calcium deposition after the cells were treated for 4 hours with a saline solution 
depleted of Na+ in the presence of the calcific stimulus 5mM Pi (“choline-saline solution”).  
In VSMCs treated with “choline-saline solution” for 2 hours every time medium was replaced 
there is a significant inhibition of calcium deposition after 7 days compared to cells 
constantly cultured in “Na+-saline solution” in presence of high Pi challenge (0.021 ± 0.001 
ctrl; 0.483 ± 0.026 5mM Pi + “Na+-saline solution”; 0.396 ± 0.021 5mM Pi + “choline-saline 
solution”; OD/mg protein; * p < 0.01)  (Fig. 15). 
 
 
 
Figure 15: Effects of “choline-saline solution” treatment during “Wash Out” period on calcium deposition  
VSMCs were cultured with 5mM Pi in the calcification medium for 7 days and calcification medium was 
replaced with “choline-saline solution” or “Na
+
-saline solution” for 2 hours every time medium was replaced. 
Ca
++ 
deposition was measured and normalized by cellular protein content. 
Data were presented as mean ± SE of four different experiments (*p < 0.01).  
 
Furthermore, to confirm the contribution of Pi influx in VSMCs during the process of vascular 
calcification, we designed an experimental condition in the attempt to limit PFA action on 
the blockage of Pi entry in VSMCs through Pit-1. To avoid PFA effect on the formation of 
hydroxyapatite crystals, we pre-incubated calcification medium with 5mM Pi at 37°C O/N to 
allow the formation of Ca-P crystals: so, the subsequent addition of PFA can not inhibit the 
passive deposition of Ca-P hydroxyapatite crystals, because they were pre-formed before 
* 
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PFA was added. Therefore, in this experimental setting, the effect of PFA on the inhibition of 
calcium deposition was only the result of inhibition of Pi influx in VSMCs. 
In VSMCs constantly exposed to high Pi treated with the “pre-incubated calcification 
medium” in the presence of 1mM PFA for 4 hours every time medium was replaced there is 
a partial inhibition of calcium deposition after 7 days compared to cells constantly exposed 
to high Pi treatment, and this inhibition is comparable to the one resulted from “Wash Out” 
treatment (0.051 ± 0.002 ctrl; 0.787 ± 0.053 5mM Pi; 0.493 ± 0.033 Pi-4h; 0.497 ± 0.023 
5mM Pi “pre-incubated” + 1mM PFA 4h; OD/mg protein; * p < 0.01) (Fig. 16). 
 
 
Figure 16: Effect of PFA treatment on the active component of calcium deposition during “Wash Out” period  
VSMCs were cultured with 5mM Pi in the calcification medium for 7 days. Some cells were cultured in absence 
of high Pi for 4 hours every time medium was replaced, and other cells were cultured in “pre-incubated 
calcification medium” with PFA for 4 hours every time medium was replaced. Ca
++
 deposition was measured 
and normalized by cellular protein content.  
Data were presented as mean ± SE of four different experiments (*p < 0.01). 
 
 
6.2.4 Effect of repeated short time free Pi and Ca-P crystals treatments on calcium 
deposition 
 
To further confirm the contribution of free Pi and to investigate the potential role of Ca-P 
crystals in VSMCs during the process of calcium deposition, we pre-incubated calcification 
medium with 5mM Pi at 37°C O/N to allow the formation of Ca-P crystals and we treated 
VSMCs only with hydroxyapatite crystals or free Pi for 4 hours every time medium was 
replaced. 
* * 
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In VSMCs constantly exposed to high Pi, but only treated with Ca-P crystals or free Pi for 4 
hours every time medium was replaced, there is a partial inhibition of calcium deposition 
after 7 days compared to cells constantly exposed to high Pi treatment: in particular, both 
the absence of free Pi and the absence of hydroxyapatite crystals in the “Wash Out” period 
result in a decrease of calcium deposition that is comparable to “Wash Out” inhibitory effect 
resulting from the absence of any form of phosphorous for 4 hours every time medium was 
replaced (0.051 ± 0.002 ctrl; 0.787 ± 0.053 5mM Pi; 0.493 ± 0.033 Pi-4h; 0.491 ± 0.033 Ca-P 
crystals 4h; 0.532 ± 0.033 free Pi 4h; OD/mg protein; * p < 0.01) (Fig. 17). 
 
 
Figure 17: Effect of Ca-P crystals and free Pi during “Wash Out” period on calcium deposition  
VSMCs were cultured with 5mM Pi in the calcification medium for 7 days. Some cells were cultured in absence 
of high Pi, others only with Ca-P crystals and others only with free Pi for 4 hours every time medium was 
replaced. Ca
++
 deposition was measured and normalized by cellular protein content.  
Data were presented as mean ± SE of four different experiments (*p < 0.01). 
 
 
6.2.5 “Wash Out” effect on the modulation of VSMC lineage markers 
 
In order to elucidate if the prevention in the progression of high Pi-induced calcium 
deposition by “Wash Out” treatment was associated with an effect on osteoblastic 
differentiation, we studied the response of 4 hours high-Pi suspension on the expression of 
VSMC lineage markers, α-actin and SM22α, after challenge with 5mM Pi. 
In our model, after 9 days high Pi down-regulates the expression of both α-actin and SM22α, 
as shown in figure 18 (α-actin 100 ± 5.72% vs 62.54 ± 3.40% and SM22α 100 ± 3.11% vs 
67.36 ± 7.80% of intensity area, control compared with 5mM Pi; *p < 0.01) (Fig. 18A-C and 
* * * 
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18B-D, respectively). The “Wash Out” treatment preserves the expression of both VSMC 
lineage markers, compared to the decreased levels of high Pi treated cells (α-actin 62.54 ± 
3.40% vs 88.08 ± 4.30% and SM22α 67.36 ± 7.8% vs 90.03 ± 5.59% of intensity area, 5mM Pi 
compared with Pi-4h; *p < 0.01) (Fig. 18A-C and 18B-D, respectively).  
 
 
Figure 18: Effects of “Wash Out” on VSMC markers expression 
VSMCs were cultured with 5mM Pi in calcification medium for 9 days, and high Pi treatment was 
 suspended for 4 hours every time medium was replaced. α-actin (panel A) and SM22α (panel B) protein 
expression was detected by immunoblotting analysis. Lane 1: control VSMCs; lane 2: 5mM Pi; lane 3: Pi-4h. 
Analysis of the intensity of the bands was shown for α-actin (panel  C) and SM22α (panel D). “Wash Out” 
prevents VSMC markers down-regulation induced by high Pi. Representative bands of one of four different 
experiments. Data were presented as mean ± SE of four different experiments (*p < 0.01). 
 
6.2.6 “Wash Out” effect on VSMC apoptosis 
Since several studies demonstrated that apoptosis is an important promoter of VSMC 
calcification, we tried to understand if “Wash Out” treatment could affect vascular 
mineralization as a consequence of a decrease of cell death. 
 
6.2.6.1 “Wash Out” effect on VSMC DNA fragmentation 
First of all, we analyzed DNA fragmentation after challenge of VSMCs with 5mM Pi for 7 days 
or with 4 hours suspension of high Pi treatment every time medium was replaced. During 
calcification process, high Pi increases cytoplasmic histone-associated DNA fragments, and 
these increase was partially inhibited after the short time high Pi suspension (1.00 ± 0.17 
ctrl; 2.92 ± 0.31 5mM Pi; 2.19 ± 0.08 Pi-4h; enrichment factor of apoptotic fragments; *p < 
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0.01) (Fig. 19). Then, we investigated if the “Wash Out” protection could be preserved at a 
later time point of the calcification process. In particular, at day 11 we obtained an increased 
inhibition of DNA fragmentation compared with day 7 (1.00 ± 0.17 ctrl; 3.18 ± 0.09 5mM Pi; 
1.92 ± 0.11 Pi-4h; enrichment factor of apoptotic fragments; *p < 0.01) (Fig. 19).  
 
 
Figure 19: Effects of “Wash Out” on VSMC DNA fragmentation 
VSMCs were cultured with 5mM Pi in calcification medium for 7 or 11 days, and high Pi treatment was 
 suspended for 4 hours every time medium was replaced. “Wash Out” prevents VSMC DNA fragmentation 
during the progression of vascular calcification.  
Data were presented as mean ± SE of four different experiments (*p < 0.01).   
 
 
6.2.6.2 “Wash Out” effect on the modulation of VSMC anti-apoptotic protein Axl expression 
Since apoptosis is the result of the activation of different molecular pathways, we decided to 
investigate if “Wash Out” treatment could involve the modulation of the anti-apoptotic and 
pro-survival marker Axl. In our model, challenge with 5mM Pi for 9 days results in a 
decreased expression of Axl, and the suspension of 5mM Pi for 4 hours every time medium 
was replaced fails to restore Axl expression at levels similar to those observed in control cells 
(69.41 ± 1.81% vs 72.63 ± 1.26% of intensity area, 5mM Pi compared with Pi-4h; n.s.) (Fig. 
20). 
* 
* 
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Figure 20: Effects of “Wash Out” on VSMC Axl expression 
VSMCs were cultured with 5mM Pi in calcification medium for 9 days, and Pi treatment was suspended for 4 
hours every time medium was replaced. “Wash Out” does not prevent the high Pi-induced down regulation of 
Axl expression. Lane 1: control VSMCs; lane 2: 5mM Pi; lane 3: Pi-4h. 
Data are presented as a representative experiment out of four (*p < 0.01). 
 
 
 
6.2.7 “Wash Out” effect on VSMC autophagy 
Since autophagy seems to be a mechanism involved in vascular calcification, we decided to 
investigate its potential modulation in “Wash Out” treatment. Autophagy is a common 
mechanism adopted by all cells for self-digestion and to degrade cellular organelles. 
 
6.2.7.1 Electron microscopy analysis 
Electronic microscopy images show that in cells continuously challenged with high Pi there 
are both calcific and healthy mithocondria: calcific mithocondria are more electron-dense, 
completely calcified and loss their structural morphology (Fig. 21A). Cells increment the 
expulsion of these calcific mithocondria (Fig. 21B) and the deposition of hydroxyapatite 
crystals at extracellular level (Fig. 21C). 
In cells that received the 4 hours high Pi suspension every time medium was replaced there 
is an increase of the autophagy: damaged mitochocondria are isolated by the cell into 
intracytoplasmatic double-membrane vesicles, that, probably, will be targeted to lysosome 
for digestion (Fig. 21D, E).  
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Figure 21: Effects of “Wash Out” on VSMC autophagy 
VSMCs were cultured with 5mM Pi in calcification medium for 9 days, and Pi treatment was suspended for 4 
hours every time medium was replaced. Arrows indicate (A) a representative calcific mithocondria, (B) 
extracellular vescicles rich in calcific mitochondria and (C) an extracellular hydroxyapatite deposit in cells 
continuously challenged with high Pi. Panels D and E represent autophagic intracellular vacuoles rich in 
damaged mitochondria in cells that received “Wash Out” treatment. 
A, B: 12,000x original magnification (insets from a 8,000x original magnification); C: 8,000x original 
magnification (inset from a 2,500x original magnification); D, E: 10,000x original magnification (insets from a 
4,000x original magnification). 
 
 
6.2.7.2 “Wash Out” effect on the modulation of VSMC autophagocitic protein LC3-II 
expression 
To confirm electron microscopy results, we decided to investigate if “Wash Out” treatment 
could involve the modulation of LC3-II autophagic marker.  
At the beginning, we analyzed LC3-II expression at day 9, and we found higher levels in high 
phosphate-challenged cells compared to control and “Wash Out”-treated cells (Fig. 22A). 
Then, since autophagy is a cell dynamic process, we decided to treat cells with chloroquine, 
an agent that impairs lysosomal acidification with the consequent blockage of LC3-II 
turnover, in order to freeze the autophagic flux at day 9. After the treatment of cells with 
this agent, we found that control and “Wash Out”-treated VSMCs show an increased 
expression of LC3-II compared to the condition “absence of chloroquine”, whereas cells 
A 
B 
 
C 
 
 
D 
E 
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A                                       B 
challenged with 5mM Pi for 9 days do not modulate LC3-II expression in presence of 
chloroquine (Fig. 22B). 
 
 
 
Figure 22: Effects of “Wash Out” on VSMC LC3-II expression 
VSMCs were cultured with 5mM Pi in calcification medium for 9 days, and Pi treatment was suspended for 4 
hours every time medium was replaced. A: Cells not treated with chloroquine: high Pi-treated cells express 
higher levels of LC3-II compared to control and “Wash Out”-treated cells B: cells treated with chloroquine: 
control and “Wash Out”-treated up-regulate LC3-II expression. 
Lane 1: control VSMCs; lane 2: 5mM Pi; lane 3: Pi-4h; Lane 4: control VSMCs+25μM chloroquine; lane 5: 5mM 
Pi+25μM chloroquine; lane 6: Pi-4h+25μM chloroquine. 
Data are presented as a representative preliminary experiment. 
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6.3 EFFECT AND MECHANISMS OF ACTION OF LANTHANUM CHLORIDE (LaCl3), 
GADOLINIUM CHLORIDE (GdCl3) AND CALINDOL ON THE DELAY OF THE PROGRESSION OF 
HIGH Pi-INDUCED VASCULAR CALCIFICATION 
 
6.3.1 Effect of LaCl3, GdCl3 and Calindol on high Pi-induced VSMC calcium deposition 
VSMCs calcify after challenge with high Pi concentration (5mM). Calcium deposition is 
concentration-dependently inhibited by addition of LaCl3, with a maximal effect at 100μM at 
day 7 of calcification (0.5 ± 0.12 ctr, 46.51 ± 2.51 5mM Pi, 32.82 ± 5.28 2µM LaCl3, 30.1 ± 
2.55 10µM LaCl3, 20.12 ± 1.33 50µM LaCl3, 19.92 ± 1.28 100µM LaCl3; µg Ca
++/mg protein; *p 
< 0.01) (Fig. 23). 
 
 
Figure 23: Effect of lanthanum on calcium deposition 
VSMCs were cultured with 5mM Pi in the calcification medium for 7 days. The presence of increasing 
concentration of lanthanum in the calcification medium induces a decrease in high Pi-induced Ca
++
 levels, that 
is statistically significant compared to high Pi alone. Ca
++
 deposition was measured and normalized by cellular 
protein content. Data were presented as mean ± SE of four different experiments (*p < 0.01). 
 
Moreover, GdCl3 inhibits calcium deposition, with a maximal effect at 50μM at day 7 of 
calcification (0.5 ± 0.11 ctr, 34.02 ± 2.53 5mM Pi, 30.5 ± 1.34 2µM GdCl3, 24.6 ± 2.52 10µM 
GdCl3, 16.97 ± 2.12 50µM GdCl3; µg Ca
++/mg protein; *p < 0.01) (Fig. 24), that is comparable 
with the inhibitory effect of LaCl3 compared to cells challenged with high Pi in absence of any 
pharmacological treatment. It was not possible to increase GdCl3 concentration above 50μM 
due to induction of cell toxicity.  
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Figure 24: Effect of gadolinium on calcium deposition 
VSMCs were cultured with 5mM Pi in the calcification medium for 7 days. The presence of increasing 
concentration of gadolinium in the calcification medium induces a decrease in high Pi-induced Ca
++
 levels, that 
is statistically significant compared to high Pi alone. Ca
++
 deposition was measured and normalized by cellular 
protein content. Data were presented as mean ± SE of four different experiments (*p < 0.01). 
 
The calcimimetic calindol inhibits calcium deposition concentration-dependently, with a 
maximal inhibition achieved at 100nM the highest concentration tested, since it was not 
possible enhance the concentration for cell toxicity induction (0.5 ± 0.11 ctr, 53.6 ± 5.32 
5mM Pi, 46.66 ± 6.09 10nM calindol, 37.23 ± 3.26 50nM calindol, 13.52 ± 2.04 100nM 
calindol; µg Ca++/mg protein; *p < 0.01) (Fig. 25). 
 
 
 
Figure25: Effect of calindol on calcium deposition 
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VSMCs were cultured with 5mM Pi in the calcification medium for 7 days. The presence of increasing 
concentration of calindol in the calcification medium induces a decrease in high Pi-induced Ca
++
 levels, that is 
statistically significant compared to high Pi alone. Ca
++
 deposition was measured and normalized by cellular 
protein content. Data were presented as mean ± SE of four different experiments (*p < 0.01). 
 
Challenging VSMCs with high-Pi for 7 days results in calcium deposition, detectable by 
Alizarin Red staining. The positive staining present in high Pi samples was inhibited by the 
addition of 100μM LaCl3, 50μM GdCl3 and 50nM calindol, and the semiquantitative analysis 
confirms that the decrease in calcium deposits is significant (0 ctr, 3.2 ± 0.1 5mM Pi, 1.8 ± 0.1 
100μM LaCl3, 1.9 ± 0.1 50μM GdCl3, 2.0 ± 0.2 50nM calindol, respectively; score 0-4; *p < 
0.01) (Fig. 26). 
 
 
Figure 26: Effect of lanthanum, gadolinium and calindol on calcium deposition 
VSMCs were cultured with 5mM Pi in the calcification medium for 7 days. Ca
++
 deposition was assessed at light 
microscopic level by Alizarin Red staining. Control VSMCs (a), 5mM Pi (b), 100μM LaCl3 (c) 50μM GdCl3 (d) and 
50nM calindol (e). a: No deposit were found in the control culture; b: Red color indicates high Pi-dependent 
deposits of Ca
++
-containing mineral; c, d and e show a decrease in Ca
++
-containing mineral deposits due to the 
inhibition of high Pi-induced calcium deposition by lanthanum, gadolinium and calindol. 
Magnification x200. Representative result of one of three different experiments. 
 
 
In order to evaluate if the prevention in the progression of high Pi-induced calcium 
deposition promoted by LaCl3 and GdCl3 was persistent at a later time point of calcification, 
we investigated the potential effect of these compounds 15 days after challenge with 5mM 
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Pi, finding that both 100μM LaCl3 and 50μM GdCl3 significantly inhibit calcium deposition (3 
± 0.1 ctr, 115.43 ± 5.85 5mM Pi, 63.1 ± 5.02 100μM LaCl3, 44.68 ± 4.57 50μM GdCl3; µg 
Ca++/mg protein *p < 0.01) (Fig. 27A).  
After challenge with high Pi for 15 days, VSMCs show a positive staining with Alizarin Red 
compared to controls (Fig. 27, B, C), which results inhibited by the addition of 100μM LaCl3 
and 50μM GdCl3 (Fig. 27, D, E). A semiquantitative analysis confirms a significant decrease in 
calcium deposition in presence of LaCl3 and GdCl3 (3.8 ± 0.1 5mM Pi, 2.1 ± 0.1 100μM LaCl3 
and 2.0 ± 0.1 50μM GdCl3; score 0-4; *p < 0.01).  
The protective role of lanthanum and gadolinium on calcium deposition is independent by 
any chelating effect on phosphate, since Pi levels in the culture medium result unchanged 
after LaCl3 and GdCl3 addition at the highest concentration (data not shown). 
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Figure 27: Effects of lanthanum and gadolinium on calcium deposition in the progression of vascular 
calcification 
VSMCs were cultured with 5mM Pi in the calcification medium for 15 days with 100μM lanthanum or 50μM 
gadolinium. A: Both lanthanum and gadolinium induce a decrease in high Pi-induced Ca
++
 levels that is 
statistically significant compared to high Pi alone. Ca
++
 deposition was measured and normalized by cellular 
protein content. Data were presented as mean ± SE of four different experiments (*p < 0.01).  
B-E: Control VSMCs (B), 5mM Pi (C), 100μM lanthanum (D) and 50μM gadolinium (E). Ca
++
 deposition was 
assessed at light microscopic level by Alizarin Red staining. B: No deposits were found in the control culture; C: 
Red color indicates high Pi-dependent deposits of Ca
++
-containing mineral; D and E show a decrease in Ca
++
-
containing mineral deposits due to the inhibition of high Pi-induced calcium deposition by lanthanum and 
gadolinium. Magnification x200. Representative result of one of three different experiments. 
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6.3.2 Effect of LaCl3, GdCl3 and Calindol on high Pi-induced VSMC osteoblastic 
differentiation 
 
6.3.2.1 Modulation of VSMC lineage markers 
In order to elucidate if the prevention in the progression of high Pi-induced calcium 
deposition by LaCl3, GdCl3 and calindol was associated with an effect on osteoblastic 
differentiation, we studied the effect of these three compounds on the expression of VSMC 
markers, α-actin and SM22α, after challenge with 5mM Pi. 
In our model, after 8 days high Pi is able to down-regulate the expression of both α-actin 
(100 ± 1% vs. 76.5 ± 1.4% of intensity area, control compared with 5mM Pi; *p < 0.01) (Fig. 
28)  and SM22α (100.0 ± 0.3% vs. 85.7 ± 2.9% of intensity area, control compared with 5mM 
Pi; *p < 0.01) (Fig. 29).  
LaCl3, GdCl3 and calindol show different effects on the modulation of α-actin and SM22α. In 
fact, the administration of LaCl3 preserves the expression of both VSMC lineage markers, 
compared to the decreased levels of high Pi treated cells (α-actin 76.5 ± 1.4% vs 103.9 ± 
2.0% (Fig. 28A) and SM22α 85.7 ± 2.9% vs 95.0 ± 4.6% of intensity area (Fig. 29A), 5mM Pi 
compared with 100μM LaCl3; *p < 0.01). In contrast, GdCl3 and calindol don’t affect high Pi- 
induced VSMC markers down-regulation (α-actin 76.5 ± 1.4% vs 60.9 ± 2.0% (Fig. 28A) and 
SM22α 85.7 ± 2.9% vs. 68.9 ± 6.2% of intensity area (Fig. 29A), 5mM Pi compared with 50μM 
GdCl3; α-actin 76.5 ± 1.4% vs 72.0 ± 2.7% (Fig. 28B) and SM22α 85.7 ± 2.9% vs 71.7 ± 1.6% of 
intensity area (Fig. 29B), 5mM Pi compared with 50nM calindol; n.s.).  
 
Figure 28: Effects of lanthanum, gadolinium and calindol on VSMC α-actin expression 
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VSMCs were cultured for 8 days in calcification medium with 100μM lanthanum, 50μM gadolinium or 50nM 
calindol and challenged with 5mM Pi. Protein expression was detected by immunoblotting analysis. A. Lane 1: 
Control VSMCs; lane 2: 5mM Pi; lane 3: 100μM LaCl3; lane 4: 50μM GdCl3. B. Lane 1: Control VSMCs; lane 2: 
5mM Pi; lane 3: 50nM calindol. Analysis of the intensity of the bands is shown for α-actin.  
Lanthanum prevents, whereas gadolinium and calindol do not affect VSMC α-actin down-regulation induced by 
high Pi. Representative bands of one of four different experiments.  
Data were presented as mean ± SE of four different experiments (*p < 0.01). 
 
 
Figure 29: Effects of lanthanum, gadolinium and calindol on VSMC SM22α expression 
VSMCs were cultured for 8 days in calcification medium with 100μM lanthanum, 50μM gadolinium or 50nM 
calindol and challenged with 5mM Pi. Protein expression was detected by immunoblotting analysis. A. Lane 1: 
Control VSMCs; lane 2: 5mM Pi; lane 3: 100μM LaCl3; lane 4: 50μM GdCl3. B. Lane 1: Control VSMCs; lane 2: 
5mM Pi; lane 3: 50nM calindol. Analysis of the intensity of the bands is shown for SM22α.  
Lanthanum prevents, whereas gadolinium and calindol do not affect VSMC SM22α down-regulation induced by 
high Pi. Representative bands of one of four different experiments. Data were presented as mean ± SE of four 
different experiments (*p < 0.01). 
 
 
To study how the modulation of VSMC markers was affected during the progression of 
calcification, we tested the expression of α-actin and SM22α at later time points.  
As shown in figure 30, also at day 9 and 12, after high Pi challenge, LaCl3 preserves both α-
actin and SM22α expression, compared to high Pi-treated cells (α-actin 75.4 ± 2.7% vs 113.5 
± 2.8% and 103.3 ± 2.3%, SM22α 80.9 ± 0.4% vs 93.3 ± 0.6% and 95.2 ± 0.4% of intensity 
area, 5mM Pi compared to 100μM LaCl3 at day 9 and at day 12, respectively; *p < 0.01). In 
contrast, with the progression of vascular calcification, GdCl3 fails to restore the down-
regulation of both VSMC markers. The expression of both VSMC markers after challenge 
with 5mM Pi is not different between day 8 and day 12 (data not shown). 
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Figure 30: Effects of lanthanum and gadolinium on VSMC markers expression during the progression of 
vascular calcification 
VSMCs were cultured for 8, 9 or 12 days in calcification medium with 100μM lanthanum or 50μM gadolinium 
and challenged with 5mM Pi. α-actin (A) and SM22α (C) protein expression was detected by immunoblotting 
analysis. Lane 1: Control VSMCs (8 days); lane 2: 5mM Pi (8 days); lane 3-4-5: 100μM LaCl3 8, 9 and 12 days 
respectively; lane 6-7-8: 50μM GdCl3 8, 9 and 12 days, respectively.  
During progression of calcification lanthanum prevents, whereas gadolinium fails to restore the VSMC markers 
down-regulation induced by high Pi. Analysis of the intensity of the bands is shown for α-actin (B) and SM22α 
(D). Representative bands of one of three different experiments.  
Data were presented as mean ± SE of three different experiments (*p < 0.01). 
 
6.3.2.2 Modulation of VSMC osteoblastic genes and proteins expression 
We next analyzed the effect of LaCl3, GdCl3 and calindol on BMP-2, Cbfα1/RUNX-2, MGP 
gene expression, all markers involved in the osteoblastic differentiation process of VSMCs, 
and the influence of LaCl3 and GdCl3 on osteonectin protein expression (SPARC).  
The time course experiment shows that, after 2 hours of incubation, the challenge with 
5mM Pi results in a peak with a 5.35 ± 0.98 fold increase in BMP-2 mRNA expression 
compared to the relative expression in normal VSMCs (t0 1.01 ± 0.06) (*p < 0.01) (Fig. 31A); 
no increase was observed at later time points (from 1 to 7 days of calcification, data not 
shown).  
Figure 31B shows that the pretreatment with LaCl3, GdCl3 and calindol partially inhibits the 
increase in BMP-2 mRNA expression induced by high Pi (4.66 ± 0.49 5mM Pi, 3.49 ± 0.14 
100μM LaCl3, 3.41 ± 0.36 50μM GdCl3 and 2.94 ± 0.43 50nM calindol relative expression; *p 
< 0.01).  
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Figure 31: Effects of lanthanum, gadolinium and calindol on BMP-2 gene expression 
VSMCs were cultured in calcification medium and BMP-2 mRNA expression was measured by RT-PCR. 
 A: Time course of BMP-2 expression after challenge with 5mM Pi. After two and four hours of high Pi challenge 
there is a significant increase in BMP-2 mRNA levels compared to the relative expression in normal VSMCs (t0). 
B: Effect of lanthanum, gadolinium and calindol on BMP-2 gene expression. Pretreatment with 100μM LaCl3, 
50μM GdCl3 and 50nM calindol induces a significant decrease in BMP-2 mRNA levels two hours after high Pi 
challenge. Data were presented as mean ± SE of three different experiments (*p < 0.01). 
 
 
Cbfα1/RUNX-2 mRNA expression has a peak 4 hours after high Pi challenge (1.65 ± 0.06 
5mM Pi, relative expression; *p < 0.01, Fig. 32A). Interestingly, no changes in Cbfα1/RUNX-2 
mRNA levels were detectable after LaCl3, GdCl3 and calindol pretreatment compared with 
the increase after high Pi challenge (Fig. 32B). 
 
 
Figure 32: Effects of lanthanum, gadolinium and calindol on Cbfα1/RUNX2 gene expression 
VSMCs were cultured in calcification medium and Cbfα1/RUNX2 mRNA expression was measured by RT-PCR.  
A: Time course of Cbfα1/RUNX2 expression after challenge with 5mM Pi. Four hours after high Pi challenge 
there is a significant increase in Cbfα1/RUNX2 mRNA levels compared to the relative expression in normal 
VSMCs (t0). B: Effect of lanthanum, gadolinium and calindol on Cbfα1/RUNX2 gene expression. Pretreatment 
with 100μM LaCl3, 50μM GdCl3 and 50nM calindol does not affect Cbfα1/RUNX2 levels four hours after high Pi 
challenge. Data were presented as mean ± SE of three different experiments (*p < 0.01). 
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We next studied the action of LaCl3, GdCl3 and calindol pretreatment on MGP mRNA levels 
modulation.  
The time course shows that, after 5 days, the challenge with 5mM Pi results in a peak with a 
35.2 ± 4.2 fold increase in MGP mRNA, compared to the relative expression in normal VSMCs 
(t0 1.1 ± 0.3) (*p < 0.01) (Fig. 33A). The increase in high Pi treated cells is significant also if 
compared with MGP mRNA levels of control cells at day 5 of culture (20.7 ± 2.6 vs 35.2 ± 4.2 
relative expression, ctr and 5mM Pi, respectively; * p < 0.01) (Fig. 33A).  
LaCl3 completely prevents the MGP mRNA increase induced by high Pi after 5 days of 
challenge (1.45 ± 0.02 vs 1.05 ± 0.05 of relative expression, 5mM Pi compared with 100μM 
LaCl3; *p < 0.01) (Fig. 33B), whereas GdCl3 does not affect high Pi-induced elevation in MGP 
levels (1.45 ± 0.02 vs 1.49 ± 0.05 of relative expression, 5mM Pi compared with 50μM GdCl3; 
n.s.) (Fig. 33B). Considering the relative expression of MGP mRNA in control cells at day 5, 
we found that the pretreatment with 50nM calindol enhances the MGP gene expression 
significantly compared to the levels in high Pi-treated cells (1.45 ± 0.02 vs 1.97 ± 0.11 of 
relative expression, 5mM Pi compared with 50nM calindol; *p < 0.01) (Fig. 33B). 
 
 
Figure 33: Effects of lanthanum, gadolinium and calindol on MGP gene expression 
VSMCs were cultured in calcification medium and MGP mRNA expression was measured by RT-PCR. VSMCs 
were cultured for 5 days in calcification medium and MGP mRNA expression was measured.  
A. Five days after high Pi challenge there is a significant increase in MGP mRNA levels compared to the relative 
expression in normal VSMCs (t0) or control VSMCs at day 5 of culture. Relative expression of MGP mRNA in 
normal VSMCs (t0) was used as reference value. B. Pretreatment with 100μM LaCl3 maintained MGP mRNA 
levels as control sample, whereas 50μM GdCl3 does not affect high Pi-induced increase in MGP mRNA. 
Pretreatment with 50nM calindol induces a significant increase in MGP mRNA levels 5 days after high Pi 
challenge. Data were presented as mean ± SE of three different experiments (*p < 0.01). 
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Osteonectin (SPARC) is a protein that, in our in vitro model, can be described as a marker of 
osteoblastic differentiation.  
We studied its expression by immunohistochemistry technique, finding that control cells 
stain faintly and in less than 10% of cells (score 0, Fig. 34A), whereas high Pi-treated cells 
stain positive in 50-60% of cells (score 3, Fig. 34B). LaCl3 and GdCl3 have a different effect on 
SPARC protein expression. In fact, LaCl3 almost completely prevents the high Pi-induced 
increase of stained positive cells (20%, score 1, Fig. 34C) and, on the contrary, cells treated 
with GdCl3 stain positive in 60% of cells (score 3, Fig, 34D). 
 
 
Figure 34: Effects of lanthanum and gadolinium on osteonectin expression 
VSMCs were cultured for 8 days in calcification medium (A), with 5mM Pi (B), in presence of 100μM lanthanum 
(C) or 50μM gadolinium (D). A faint positivity was observed in osteonectin immunostaining in control sample 
(A); a more intense staining was observed after treatment with high Pi (B); a pattern similar to control was 
detected after pretreatment with lanthanum (C) whereas a pattern similar to high Pi-treated sample was 
detected after gadolinium pretreatment (D). Representative result of one of two different experiments. 
 
6.3.3 Effect of LaCl3 and GdCl3 on the modulation of VSMC anti-apoptotic Axl protein 
expression 
In our model, challenge with 5mM Pi for 8 days results in a decreased expression of the anti-
apoptotic protein Axl as shown in figure 35 (113.2 ± 2.8% vs 94.2 ± 1.5% of intensity area, 
control compared to 5mM Pi; *p < 0.01). Interestingly, both 50μM and 100μM LaCl3 preserve 
the expression of Axl protein to levels similar to control and significantly higher compared 
with high Pi-treated cells (94.2 ± 1.5% vs 104.1 ± 1.3% and 108.4 ± 2.1% of intensity area, 
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5mM Pi compared to 50μM LaCl3 and 100μM LaCl3, respectively; *p < 0.01) (Fig. 35A). On the 
contrary, 50μM GdCl3 and 50nM calindol fail to restore Axl expression, without affecting the 
high Pi effect on this protein expression (94.2 ± 1.5% vs 94.7 ± 2.7% of intensity area, 5mM Pi 
compared to 50μM GdCl3 (Fig. 35A) and 82.2 ± 4.9% vs 91.1 ± 5.1% of intensity area, 5mM Pi 
compared to 50nM calindol (Fig. 35B); n.s.). 
 
Figure 35: Effects of lanthanum, gadolinium and calindol on Axl expression 
VSMCs were cultured for 8 days in calcification medium with lanthanum, gadolinium or calindol and challenged 
with 5mM Pi. Axl protein expression was detected by immunoblotting analysis. A. Lane 1: Control VSMCs; lane 
2: 5mM Pi; lane 3: 50μM LaCl3; lane 4: 100μM LaCl3; lane 5: 50μM GdCl3. B. Lane 1: Control VSMCs (106.2 ± 
26.1%); lane 2: 5mM Pi; lane 3: 50nM calindol. Analysis of the intensity of the bands is shown. 
 Lanthanum prevents, whereas gadolinium and calindol do not affect the high Pi-induced Axl down-regulation. 
Representative bands of one of three different experiments. Data were presented as mean ± SE of three 
different experiments (*p < 0.01). 
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7. DISCUSSION  
 
Vascular calcification is associated with significant cardiovascular morbidity and mortality in 
patients with chronic kidney disease. Factors unique to CKD patients, such as 
hyperphosphatemia, predispose these subjects to early and progressive vascular calcium 
deposition. Hyperphosphatemia appears to be involved in a number of mechanisms that 
trigger and cause the progression of vascular calcification, including transition of vascular 
smooth muscle cells from a contractile to an osteochondrogenic phenotype, induction of 
apoptosis in VSMC and inhibition of autophagy.  
In light of these pathological events high Pi mediated, it is important to limit vascular 
calcification in CKD patients through pharmacological therapy and dialysis, in order to 
control phosphate levels.  
It is, also, important to elucidate which are the molecular events that trigger VSMCs to 
deposit calcium in the tunica media of vessels, and which are the promoter and inhibitor 
proteins involved in this pathological process in the attempt to design drugs to down-
regulate the formers and to up-regulate the latters, with the final intent that control this 
pathological process.  
Moreover, the knowledge of cellular and molecular events that lead to the pathogenesis of 
vascular calcification is useful to avoid the administration of therapy that, in any way, could 
interfere with the activity of proteins involved in these pathways and, consequently, made 
the CKD patients clinical situation worse.  
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7.1 MODULATION OF OSTEONECTIN EXPRESSION IN VASCULAR CALCIFICATION 
PATHOGENESIS 
Osteoblastic transformation of VSMCs is one of the most important processes involved in 
vascular calcification, a multifactorial pathological process that results from an imbalance 
between the promoters and inhibitors of mineralization.  
In our study, we decided to investigate the role of osteonectin, a major non-collagenous 
protein of bone matrix, in vascular calcification. Nevertheless there are some controversial 
results about its modulation during the process of vascular calcification, we have evidence 
that, in our model, it has a pro-calcificant role. 
First of all, we investigated the time course expression of osteonectin in VSMCs challenged 
with 5 mM Pi in the attempt to understand its modulation with the progression of vascular 
calcification. We discovered that both control and high Pi-treated VSMCs are positive for 
osteonectin, with an up-regulation in cells treated with high-Pi compared to control. In high 
Pi-challenged VSMCs, the maximal osteonectin expression is at day 7. Its subcellular 
localization changes during the time course: indeed, until day 4, osteonectin is expressed 
only at a perinuclear level, to be expressed in the cytoplasm starting from day 7, where it is, 
presumably, destined for secretion. 
To better understand if osteonectin is involved in the calcification process, we decided to 
correlate its time course expression with the progression of calcium deposition. At day 7, 
when osteonectin has a maximal expression, Von Kossa staining shows a massive calcium 
deposition in VSMCs cultivated in calcification medium.  
Until now, we have evidence that osteonectin expression is induced in calcificant conditions, 
but we can not infer any conclusion about its role in VSMCs. Young et al demonstrated that 
osteonectin can regulate cell proliferation (135), so, to better understand the regulation of 
this protein in our model, we decided to study the correlation between its expression and 
cell proliferation. We investigated the time course expression of the proliferative nuclear 
marker Ki-67, demonstrating that, in calcific VSMCs, the maximal peak for Ki-67 is at day 4. 
The maximal expression of osteonectin and Ki-67 do not occur at the same time point, so, 
probably, the main role of osteonectin in our model is not the regulation of cell proliferation. 
Then, since the agreement between the results of calcium deposition and osteonectin 
expression, we decided to elucidate the role of osteonectin in high Pi-induced calcification. 
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So, we investigated the time-course expression of Cbfα1/RUNX-2, the master gene involved 
in bone differentiation and in VSMCs osteoblastic transformation in calcific conditions. We 
found a maximal expression of Cbfα1/RUNX-2 at day 7, just like osteonectin. So, we started 
to suppose that osteonectin expression could be correlated with vascular calcification. Then 
we tried to associate its expression with another factor that we have previously 
demonstrated to be involved in the promotion of the mineralization process in vitro: 
ascorbic acid (AA). Therefore, we decided to study the modulation of osteonectin in VSMCs 
challenged with 5 mM Pi in presence and absence of AA, to understand if its regulation could 
be correlated with this cofactor of calcium deposition in vitro. The results show that AA 
modulates osteonectin expression: at day 7, the high Pi-induced calcification in absence of 
AA decreases of 60.8% compared to the high Pi-induced calcification in presence of AA. The 
positive association between Cbfα1/RUNX-2 elevation and AA presence with osteonectin 
expression supports a role for this protein in the high Pi-induced calcification of VSMCs.  
The observation that osteonectin expression was induced in VSMCs in vitro in calcific 
conditions suggested that it could be involved in regulating the osteo/chondrocytic 
transition of VSMCs in vivo, so we decided to study its expression ex-vivo in fetal, adult non 
calcific and adult calcific atherosclerotic vessels. For the first time in our knowledge, we 
show a high expression of osteonectin in fetal VSMCs that is consistent with its involvement 
in processes such as tissue renewal, remodeling, and embryonic development. The 
localization of osteonectin in the active proliferating fetal VSMC indicates a potential role of 
this protein in mitosis regulation during development. Moreover, as expected, in adult 
specimens osteonectin is constitutively present with a faint staining that increases as 
calcification progresses, showing osteonectin expression in the residual VSMCs, which 
become displaced by fibrous tissue as the atherosclerotic plaque develops. Our findings are 
in agreement with the results by Dhore et al (45), considering osteonectin as a potential 
promoter of vascular calcification, but they are in contrast with those by other groups, which 
consider osteonectin as an inhibitory protein, down-regulated during arterial calcification 
(52-54). 
 
In conclusion, although there are some controversial points of view about the modulation of 
osteonectin during the process of vascular calcification, our in vitro results allow us to 
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suppose that this protein could be involved in VSMC osteoblastic transformation, first of all 
because its maximal expression, in calcific conditions, is at the same time point in which 
there is the maximal osteoblastic transformation, and, then, because it is modulated in 
response to a cofactor of in vitro calcium deposition as ascorbic acid. 
Our ex vivo data on human arteries support our in vitro data validating the hypothesis that 
the increase in osteonectin levels in sites of calcium deposition actively participates to the 
calcification process. These data may be of potential interest for better elucidate the 
pathogenesis of accelerated atherosclerosis in uremic patients that suffer of both 
hyperphosphatemia and vascular calcification. 
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7.2  “WASH OUT” EFFECTS ON VASCULAR CALCIFICATION 
 
Known the abilities of VSMCs to remodel their phenotypic characteristics in response to 
environment changes and known the key role of high phosphorous on vascular calcification 
and on osteoblastic differentiation of VSMCs, the main purpose of this in vitro studies was to 
investigate the mechanism of high Pi-induced vascular calcification: in particular, we 
analyzed the effect of temporary and repeated suspension of high Pi on the progression of 
vascular calcification (process that we called “Wash Out”) in order to develop an 
experimental model that can simulate in vitro the haemodialysis treatment. Our purpose 
was to investigate the high Pi impact on vascular calcification and the potential benefits that 
“Wash Out” could afford in terms of prevention of calcium deposition. 
The present study demonstrates that “Wash Out” treatment partially protects vascular 
smooth muscle cells from high-Pi-induced calcification: it is a very innovative discovery in the 
field of vascular calcification, because this is the first time that the effect of short term high-
Pi suspension on VSMC calcium deposition demonstrates an efficacy in vitro, without the use 
of any pharmacological treatment.  
First of all, we studied the “Wash Out” effect on VSMC calcium deposition and we 
demonstrated not only that there is a beneficial effect on vascular calcification as a 
consequence of short time high Pi suspension, but, also, that the inhibition of calcium 
deposition depends on the duration of this suspension: longer is the time of high Pi 
suspension, higher is the inhibition of calcium deposition compared to cells constantly 
exposed to high Pi. In particular, in cells that received the “Wash Out” treatment for 4 hours 
every time medium was replaced there is a high and significant inhibition of calcium 
deposition, about 35-40%, compared to cells continuously challenged with high Pi. It is 
surprising that the suspension of high-Pi treatment for only 8 hours during 7 days of 
calcification can induce a so consistent and significant inhibition of calcium deposition. So, 
although high Pi is a very strong trigger of VSMC calcification, these results suggest that it is 
enough a short time high Pi suspension to delay VSMC calcium deposition.  
Then, we investigated if the number of high Pi suspensions could have an effect on calcium 
deposition. In 7 day experiments, high Pi was suspended twice for only 8 hours overall, 
whereas in 10 day experiments three times for 12 hours overall: we don’t find relevant 
differences in terms of “Wash Out” protective effects on calcium deposition, being these 
76 
 
percentages of inhibition comparable (35.78% and 45.16% of inhibition, day 7 and day 10 of 
calcification, respectively). In 10 days experiments, cells were cultured in the presence of 
15% fetal bovine serum to allow them to grow healthily and to avoid apoptosis and necrosis 
events, because dead cells are foci for calcium deposition. Therefore, when the calcification 
model is set up, the “Wash Out” protective effect is kept and it is independent from the 
number of times of high Pi suspension, but is clearly dependent on the duration of the pro-
calcific stimulus suspension. 
To confirm that the final protective effect of “Wash Out” treatment is really due to short 
high Pi suspension, we decided to culture cells in continuously presence of high Pi and, 
rather than suspend the challenge for 4 hours every time medium was replaced, we added 
Phosphonoformic acid (PFA) for the same “Wash Out” period, in order to mimic the total 
absence of phosphorous in our in vitro model for short periods, and we analyzed the final 
effect on calcium deposition. It is important to mention that in our in vitro model inorganic 
phosphate can exist in 2 forms, free soluble Pi and as insoluble hydroxyapatite crystals. PFA, 
besides to be a competitive inhibitor of sodium-dependent phosphate co-transporter (Pit-1), 
able to induce a dose-dependent inhibition of VSMCs phosphate uptake, it is, also, an 
inhibitor of hydroxyapatite crystal formation, preventing nucleation in a similar way to 
pyrophosphate and bisphosphonates (87, 119). Therefore, in the presence of PFA, 
phosphorous can not enter in VSMCs and can not precipitate as crystals. In our in vitro 
model, short time PFA treatment confirms the “Wash Out” results in terms of inhibition of 
vascular calcification: in cells treated with PFA for the same “Wash Out” period every time 
medium was replaced there is an inhibition of calcium deposition of 42% compared to cells 
constantly exposed to high Pi levels during 7 days calcification process, and this protective 
effect is comparable to those resulting from the “Wash Out” treatment.  
This supplementary study confirms that the delay on the progression of VSMC calcium 
deposition in “Wash Out” model is really due to the temporary and repeated absence of high 
Pi, supporting the relevant role of high Pi on vascular calcification.  
As already mentioned, extracellular Pi enters into the intracellular compartment via a 
sodium-dependent phosphate co-transporter (Pit-1)-mediated pathway. This influx increases 
during hyperphosphatemia and it leads to the accumulation of intracellular phosphate. By 
pathways that have not yet been fully elucidated, the increased intracellular phosphate acts 
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as a promoter signal for osteogenic gene expression (Cbfα-1 and downstream targets 
osteopontin and osteocalcin) and as a suppressor of smooth muscle cells specific gene 
expression, resulting in increased secretion of mineral-nucleating molecules (matrix vesicles, 
calcium-binding proteins, alkaline phosphatase, and collagen-rich extracellular matrix) (75). 
Given the importance of Pi influx in VSMCs to promote vascular calcification, Pit-1 has a 
central role in the pathogenesis of calcification: numerous studies demonstrated that the 
suppression of endogenous sodium-dependent phosphate co-transporter in VSMCs by small 
interfering RNAs (siRNAs) prevents high-Pi-induced VSMC calcification in vitro (84), that the 
Na/Pi co-transporter inhibitor PFA prevents calcification and osteogene expression in the 
presence of hyperphosphatemic concentrations (75, 87) and that Pit-1 expression in VSMCs 
increases under some calcifying conditions (75, 124, 136). 
As already mentioned, inorganic phosphate, besides to be a soluble signaling molecule, can 
precipitate as insoluble hydroxyapatite crystals: it has been recently reported that 
hydroxyapatite crystals alone are able to induce the process of VSMC osteogenic 
transformation. Sage et al. demonstrated that purified synthetic hydroxyapatite nanocrystals 
and isolated hyperphosphatemia-induced nanocrystals, up-regulate the expression of Bmp-2 
(bone morphogenetic protein-2) and osteopontin genes in VSMCs in vitro (25). It is possible 
that nanocrystals directly affect DNA transcription complexes, as they have been reported to 
enter the nucleus and interact with histones (137). However, the molecular mechanisms or 
pathways by which these nanocrystals act on gene expression are not fully elucidated. The 
findings of Sage et al. support the view proposed by Shanahan (138) that vascular calcium 
crystals are far from inert and may promote the pro-inflammatory, pro-osteogenic 
environment associated with vascular calcification. Some studies demonstrated that 
nanocrystals have pleiotropic effects, including the induction of inflammatory cytokines in 
macrophages, mitogenesis and matrix metalloproteinases in osteoblasts and fibroblasts, 
autophagy, and, under serum-free conditions, the induction of apoptosis in VSMCs (138).  
In our experimental conditions, we add 5 mM Pi to cells to induce vascular calcification, and 
this high concentration is over the solubility of Ca x Pi product: therefore, Pi can not be 
totally in solution, but it also precipitates as insoluble crystals together with other cations 
like Ca++.  
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First of all, we measured the concentration of free Pi and of Pi complexed in hydroxyapatite 
crystals, and we found that it was the same, about 2.5mM.  
Since inorganic phosphate can act in these two forms, one of the aim of our experiments 
was to elucidate what is the single potential contribute of free Pi and hydroxyapatite crystals 
during the 4 hours of repeated high Pi suspension on 7 days calcium deposition: in other 
words, we decided to plan different experimental strategies to investigate the effect of the 
absence of free Pi or hydroxyapatite crystals during the “Wash Out” period on the delay of 
the progression of VSMC calcium deposition. 
Therefore, as a first experimental approach, we decided to study the modulation of calcium 
deposition in response to the blockage of Pi influx in VSMCs through Pit-1 during the 
repeated and short time high Pi suspensions, in order to elucidate only the contribution of 
hydroxyapatite crystals during the “Wash Out” period on calcium deposition: in this way, we 
can demonstrate the relevance of Pi influx blockage in VSMCs on the prevention of high Pi-
induced vascular calcification in our in vitro model. To answer to this question, we planned 
three different experimental strategies: in the former, we temporary blocked Pi entry in 
VSMCs by Pit-1 through the elimination of the Na+ gradient, that is necessary to allow Pi 
influx in cells; in the second, we tried to address PFA protective action only on the blockage 
of Pi entry in VSMCs, trying to eliminate the contribute of PFA effect on hydroxyapatite 
crystals formation; in the latter, we directly investigated the single contribute of 
hydroxyapatite crystals on calcium deposition during the “Wash Out” period. 
For the first approach, we decided to replace calcification medium with a “choline-saline 
solution” for a short period every time medium was replaced in continuously presence of 
high-Pi. In this set of experiments, some cells were treated for short periods with “choline-
saline solution”, in which sodium was replaced with choline, a molecule able to maintain 
cellular osmotic pressure, but too large to be co-transported with Pi into VSMCs through Pit-
1. Treating the cells with this saline solution for 4 hours every time medium was replaced 
resulted in cell death: probably because the cells were in absence of serum, amino acids and 
vitamins, that are essential components of calcification medium and that are, probably, 
necessary to limit the toxic effect of high Pi. So, we decreased the period of this temporary 
treatment from 4 to 2 hours. Replacing sodium with choline abolishes phosphate uptake by 
VSMCs: with the short time blockage of Pi influx in VSMCs every time medium was replaced, 
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there is a 18% of inhibition of vascular calcification compared to cells constantly challenged 
with high-Pi in the presence of a Na+ gradient.  
For the second approach, we used a pharmacological treatment: in particular, we addressed 
PFA action only on the blockage of Pit-1, and not on the inhibition of hydroxyapatite crystals 
formation by pre-incubating calcific medium O/N at 37°C to allow the formation of 
hydroxyapatite crystal. Even with this experimental strategy, we confirmed that the 
consequence of short and repeated Pi influx suspensions in VSMCs is an inhibition of calcium 
deposition of 37% compared to cells constantly challenged with high Pi for 7 days, and this 
inhibition is about the same resulting from “Wash Out” treatment. It means that the only 
presence of hydroxyapatite crystals for repeated short period leads to a final calcium 
deposition comparable to those resulting from “Wash Out” condition. 
Finally, even with the third approach, we demonstrated that in absence of free Pi and with 
the only presence of hydroxyapatite crystals for the “Wash Out” period, calcium deposition 
results inhibited for 37% compared to cells constantly challenged with high Pi for 7 days. 
These results lead us at the conclusion that the absence of free Pi and, therefore, the only 
presence of hydroxyapatite crystals for repeated short period leads to a inhibition of calcium 
deposition comparable to those resulting from “Wash Out” condition. 
Therefore, as a second experimental approach, we investigated the other side of the coin, 
that is the modulation of calcium deposition in response to the only presence of free Pi 
during the repeated and short time high Pi suspensions: in this way, we can deduce the 
relevance of the short period absence of hydroxyapatite crystals on the prevention of high 
Pi-induced calcium deposition in our in vitro model. The consequence of short and repeated 
suspensions of Ca-P crystals during the “Wash Out” period is an inhibition of calcium 
deposition of 37% compared to cells constantly challenged with high Pi for 7 days, about the 
same resulting from “Wash Out” treatment and from the only presence of hydroxyapatite 
crystals during the “Wash Out” period. 
Therefore, the results of these different experimental strategies demonstrate that both the 
temporary absence of Pi entry in VSMCs and the temporary lacking of Ca-P crystals presence 
during 7 days of high Pi challenge lead to a unique and unquestionable result, that is the 
partial inhibition of calcium deposition compared to cells continuously high Pi-challenged: 
interestingly, the percentages of inhibition resulting from the temporary absence of one of 
80 
 
the two Pi components are the same and they are comparable to the percentage of 
inhibition obtained from the total absence of high Pi during the “Wash Out” period.  
So, we can infer that it is not relevant challenging VSMCs either with (free Pi or Ca-P crystals) 
to partially prevent VSMC calcification during “Wash Out” period, but what is important is 
temporarily decrease Pi challenge under a so called trigger threshold, even for short period, 
during the process of calcification to obtain a substantial inhibition of calcium deposition 
after 7 days of high Pi conditions. When cells are temporarily challenged only with free Pi or 
hydroxyapatite crystals, they are exposed to an under threshold phosphorous burden, that is 
about the half compared to the total high Pi used to challenge cells during the calcification 
process (2.5-3mM vs 5mM), and this condition prevents VSMC calcium deposition in the 
same extend as the total absence of phosphate in the “Wash Out” experiments. The 
relevance of the Pi threshold on the final event of calcium deposition was demonstrated 
even in the set of experiments that correlates the duration of the “Wash Out” period with 
the prevention of calcium deposition, where longer was the “Wash Out” period, longer was 
the time in which Pi levels were under the threshold, and, as a result, higher was the 
prevention of calcium deposition. 
These results confirm that the mechanism of action of Pi in the process of VSMC calcification 
is a so called “on-off” mechanism: when Pi levels are under the threshold, that in our in vitro 
model is about 4.5-5mM, the load of phosphorous that cells sense is not sufficient to trigger 
all a series of intracellular events that lead them to deposit calcium; however, it is sufficient 
a little bit ovestep of the threshold (to begin from 5mM Pi) to suddenly “switch on” these 
events, with the final effect of VSMC calcium deposition. Given that in wash out 
experiments, in the “threshold” periods cells freeze the processes that finally lead to calcium 
deposition because the action of Pi is “off”, the final effect is a surprising and significant 
reduction of calcium deposition compared to cells constantly challenge with high Pi for 7 
days (about 40% of of calcium deposition inhibition). 
These experimental observations suggest how is important to limit high Pi contact with 
VSMCs to delay the progression of vascular calcification. Our in vitro results demonstrate 
that the simply suspension of the pro-calcific factor “high-Pi” for 8 hours during 7 days high 
Pi-treated VSMCs has a very significant impact on the inhibition of calcium deposition. This in 
vitro discovery can suggest that it should be opportune to increment the duration of 
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haemodyalisis cycles in CKD patients, and so, to increment the duration of the under 
threshold condition, in the attempt to control as more as possible phosphatemia. It was 
already demonstrated that nocturne haemodyalisis is the gold standard to decrease 
phosphoremia in CKD patients, since they do not need to assume any phosphate binders 
pharmacological therapy. Since longer is the duration of haemodyalisis, longer is the time in 
which cells are exposed to an under threshold circulating Pi level, we could suppose that the 
result of an increment of the time in which VSMCs are not exposed to high Pi could be the 
decrease of vascular calcification (139). 
The final effect of “Wash Out” is the reduction of calcium deposition, but we don’t know 
what are the mechanisms involved. Since VSMC calcification is a multifactorial process that 
arises from the modulation of different biological pathways, in the “Wash Out” experiments 
we decided to focus our attention on the study of the potential mechanisms involved in this 
protective process, as the modulation of VSMC lineage markers, apoptosis and autophagy.  
First of all, we investigated the effect of “Wash Out” treatment on the modulation of 
vascular smooth muscle cell markers expression. Under normal conditions, VSMCs express 
smooth muscle lineage markers, including α-actin and SM22α. We demonstrated that 
treatment with high Pi causes a loss of SM lineage markers, but their expression was almost 
fully recovered with a 4 hours suspension of 5mM Pi every time medium was replaced. The 
percentage of inhibition of α-actin expression by 5mM Pi compared to control condition is 
37.5%, while Pi-4h caused a down-regulation equal to 12.0% compared to control condition; 
in 4h high Pi treatment suspension condition there is a recovery equal to 68% of α-actin 
expression. The same percentage of recovery is achieved also after “Wash Out” treatment 
for SM22α expression.   
Therefore, we demonstrated that at least one mechanism by which “Wash Out” exerts a 
protective effect on calcium deposition is the prevention of high Pi-induced down-regulation 
of VSMC markers, with the preservation of a muscular cell phenotype and the inhibition of 
their simil-osteoblastic transformation. It is important that VSMCs can keep their contractile 
phenotype to contrast cardiovascular events. However, it could be very interesting to study 
“Wash Out” effects on the modulation of osteoblastic markers in next experiments.  
It’s not clear if the protective effect of high Pi suspension involves homogeneously all cells, 
that become able to partially arrest or decelerate calcium deposition or osteoblastic 
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transformation, or if it is the result of the response of only a subgroup of cells. Being calcium 
deposition a focal process in vitro, if the transformation corresponds to calcification foci, we 
can hypothesize that some cells do not transform themselves, some arrest their 
transformation process at a middle level, and others complete their osteoblastic 
transformation.  
After the study of the potential “Wash Out” effects on VSMC markers modulation, we 
investigated whether high Pi suspension could be involved in the prevention of cell 
apoptosis. Since it is known that apoptosis is involved in VSMC calciﬁcation and that 
apoptotic bodies derived from VSMCs may act as nucleating structures for calcium crystal 
formation, we decided to investigate if “Wash Out” treatment could prevent this pro-
calcificant event: in particular, we focused our attention on the modulation of DNA 
fragmentation, that it is the final event of cell apoptosis. We demonstrated that “Wash Out” 
prevents high Pi-induced VSMC apoptosis by the decrease of DNA fragmentation: in cells 
that received a 4 hours high Pi suspension every time medium was replaced there is a 
partially DNA fragmentation reduction compared with cells continuously exposed to high Pi. 
This “Wash Out” anti-apoptotic effects is maintained during the progression of vascular 
calcification, until 11 days of culture in calcification medium, with a major protection at day 
11 compared to day 7 (39.6% and 25.0%, respectively), probably because these cells 
received a supplementary “Wash Out”.  
Since “Wash Out” modulates DNA fragmentation, we investigated a potential anti-apoptotic 
pathway that has been demonstrated to be involved in high Pi-mediated apoptosis to find 
out whether it could be modulated by “Wash Out” treatment: the Axl-Gas6 pathway. To 
maintain cell survival, the binding of Gas6  to  its  cognate  receptor  Axl  induces  
phosphatidylinositol 3-OH  kinase  (PI3K)  activation  and  subsequent Akt activation, 
showing sequential events of the Gas6/Axl/PI3K/Akt signal (35). In our experimental model, 
the downregulation of Axl associates with calcification, whereas the maintenance of its 
normal levels with the prevention of VSMC calcification; neverthless, despite the anti 
apoptotic action of “Wash Out” on DNA fragmentation to prevent VSMC apoptosis, it seems 
that the temporary high Pi suspension does not affect the modulation of Axl and this 
pathway in our in vitro model. However, it is known that high Pi can affect apoptosis by 
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other pathways, for example it can modulate the caspase 3 and 9 activity and can modulate 
the activity of mithocondrial citocrome c. 
Finally, we started to investigate the “Wash Out” effect on a potential mechanism that 
seems to be involved in vascular mineralization: autophagy. Autophagy is a dynamic and 
highly regulated process of self-digestion responsible for cell survival and reaction to 
oxidative stress. Dai et al. recently demonstrated that calcium deposition in VSMCs increases 
during inhibition of autophagy (116), defining autophagy in the high Pi model as a protective 
mechanism with respect to calcium deposition. So, we decided to use electron microscopy 
as a first qualitative approach to elucidate whether high Pi suspension could modulate this 
anti-calcific process. Electron microscopy is the most appropriate technique to study fine 
ultrastructural modifications that accompany cell death and autophagy. Our results show an 
increment of autophagic structures in VSMCs that received “Wash Out” treatment compared 
to cells continuously exposed to high Pi. Electron microscopy images show that “Wash Out” 
treated cells try to preserve their vitality by the isolation of damaged organelles in double-
membrane vesicles (autophagosomes) that will be, probably, targeted to lysosomes to be 
digested in intracellular structures called autophagolysosomes in order to create new 
nutrients for survival and to selectively remove damaged mitochondria, in the attempt to 
prevent the activation of apoptotic pathways that lead, as a last stage, to calcium deposition. 
Moreover, whereas VSMCs that received “Wash Out” treatment show increased 
autophagosomes, cells continuously exposed to high Pi are rich in calcific mitochondria, that 
are at a higher degenerative stadium than “Wash Out” mithocondria. The high Pi-treated 
cells implement the expulsion of calcific organelles, as shown by the electron microscopy 
images, probably because in these cells autophagy can not afford to eliminate all the 
damaged mithocondria, and some of them calcify inside the cells before the cell can, in any 
way, eliminate them. In cells continuously challenged with high Pi, mithocondrial 
calcification certainly could lead to organelles dysfunction, like the decrease of 
mitochondrial membrane potential and ATP production and the concurrently increased 
production of reactive oxygen species. In VSMCs that received “Wash Out” treatment, 
mitochondria are less calcified and more structurally preserved, and it could be one of the 
reasons that lead to a decrease in VSMC apoptosis. So, in next experiments we would like to 
focalize the study of apoptosis on mitochondrial-dependent apoptotic events, including 
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release of cytochrome c from the mitochondria into the cytosol and subsequent activation of 
caspase-9 and -3, proteins involved in DNA fragmentation apoptotic pathway. 
Although electron microscopy can provide an impressive amount of ultrastructural 
information, the visual inspection of electron microphotographs should always be 
complemented by a quantitative approach. So, to support these qualitative results, we tried 
to elucidate the autophagy process by the western blot analysis, and we investigated the 
modulation of an autophagocitic marker, LC3-II (Light Chain 3-II), to ensure the involvement 
of this process in VSMC calcification. Analyzing this marker, we demonstrated that cells 
continuously challenged with high Pi express higher levels of the autophagic marker 
compared to control and “Wash Out”-treated cells. Since autophagy is a dynamic cell 
process, the accumulation of autophagosomes is not always indicative of autophagy 
induction, and may represent either the increased generation of autophagosomes and/or 
block in autophagosomal maturation and the completion of the autophagy pathway. So, we 
analyzed the expression of this marker monitoring “autofagic flux” by western blot assay: we 
treated cells with chloroquine, an agent that impairs lysosomal acidification and stops 
autophagosomes degradation, with the consequent block of the basal LC3-II turnover and 
the accumulation of this marker. Results show that the difference in LC3-II levels in the 
presence and absence of chloroquine is larger in control and in “Wash Out”-treated cells 
than in high Pi-challenged VSMCs, indicating an increment of the autophagic flux in the 
former conditions. Western blot analysis leads us to suppose that, probably, cells 
continuously challenged with high Pi activate autophagy process, because they are exposed 
to stress conditions: so they “switch on” this protective mechanism in the attempt to 
survival, and it is indicated by high LC 3-II levels in absence of chloroquine. However, they 
aren’t able to complete the process, and it is demonstrated by “autofagic flux “experiment, 
where we found similar levels of LC3-II in the presence and absence of chloroquine: this 
result suggests that in high stress condition, the completion of the autophagy pathway is 
suppressed, resulting in decreased autolysosomal degradation of LC 3-II. Probably, high Pi 
condition are too toxic to maintain this life-and-death struggle, and when they are too 
stressed to try to maintain their survival, they surrend themselves and they go towards 
apoptosis. Interestingly, in “Wash Out” condition there is an increment of the autophagic 
process probably because cells are in better health compared to cells continuously 
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challenged with high Pi: in these repeated short time periods in which Pi action is “switch 
off”, they try to protect themselves further activating autophagy in order to eliminate the 
damaged intracellular structures to survive. 
 
In conclusion, hyperphosphatemia appears to be involved in a number of mechanisms that 
trigger and cause VSMC pathological calcium deposition: when Pi levels are over a threshold, 
that in our in vitro model coincide with 5mM, cells are stimulated to “switch on” all a series 
of intracellular events Pi-dependent, including their transformation from a contractile to an 
osteochondrogenic phenotype, induction of apoptosis and decreasing in autophagic 
protective process, that, all together, lead them to deposit calcium at an extracellular level.  
As we demonstrated in our in vitro model, when we challenged VSMC with high Pi, this 
inorganic ion is present in two different forms, free Pi and as hydroxyapatite, respectively: 
both of these Pi types act synergically on cells leading to VSMC calcification.  
To obtain the pathological VSMC calcium deposition, what is really important is the presence 
of high Pi level that overstep the threshold. Effectively, when VSMCs are continuously 
challenged with over threshold Pi levels, Pi action is constantly “switch on” and cells respond 
to this constant pro-calcific stimulus triggering and perpetuating their pathological calcium 
deposition. On the contrary, both in “Wash Out” model, where VSMC high Pi treatment is 
temporarily suspended, and treating cells for short periods with Pi levels that are under 
threshold, it is clearly evident the surprising benefit on the delay of the progression of 
vascular calcification. Surprising, all the high Pi-modulated intracellular processes that trigger 
VSMC calcium deposition (down-regulation of VSMC markers and autophagy, and up-
regulation of VSMC apoptosis) are delayed because cells are challenged with “under 
threshold” Pi levels only for short periods compared to the 7-11 days of high Pi conditions, 
but these repeated and short periods are sufficient to temporarily freeze VSMC 
transformation process and apoptosis with a substantial and significant inhibition of the final 
calcium deposition.   
In light of the high Pi pathological action on VSMC calcification process and of the protective 
effects of the in vitro “Wash Out” mechanism, it is of primary importance to decrease the 
time of contact between arteries and high Pi in dialysis patients in the attempt to reduce 
VSMC calcification and the consequent risk of cardiovascular events: for example, it will be 
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opportune to prolong haemodialysis cycles to limit the time in which VSMC are exposed to 
an high Pi loading.  
Understanding the role of phosphate and improving the management of 
hyperphosphatemia is of relevant importance. Despite the signiﬁcant amount of knowledge 
in the ﬁeld, important questions remain to be answered. Whether vascular calcification can 
be prevented or reversed with strategies aimed at maintaining phosphate homeostasis 
presently is not fully elucidated. 
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7.3 EFFECT AND MECHANISMS OF ACTION OF LANTHANUM CHLORIDE (LaCl3), 
GADOLINIUM CHLORIDE (GdCl3), AND CALINDOL ON THE DELAY OF THE PROGRESSION OF 
HIGH Pi-INDUCED VASCULAR CALCIFICATION 
 
Vascular calcification represents a major cardiovascular risk factor in chronic kidney disease 
patients and high phosphate levels are strongly associated with vascular calcification in this 
population. In dialysis patients, hyperphosphatemia can be reduced by the control of oral Pi 
intake, an adequate dialysis treatment, and the use of intestinal Pi-binders. In particular, the 
use of calcium-free Pi-binders, such as lanthanum carbonate, appears to be an essential part 
of the treatment to control  Pi  overload,  reducing  the  risk  of  hypercalcemia  and  vascular 
calcification (140). 
Moreover, high serum phosphate levels associate with secondary hyperparathyroidism 
(SHPT), and, to control this complication, dialysis patients are treated with active vitamin D 
and/or the calcimimetic cinacalcet (141). Beyond SHPT control, calcimimetics have been 
investigated as new potential tools to control vascular calcification. In animals affected by 
renal failure, Lopez et al. demonstrated  that  treatment  of  SHPT  with  active  vitamin  D,  
but  not  with  calcimimetics,  was associated with the development of vascular calcification 
(142). Recently, it has been also reported a reduced expression of the calcium sensing 
receptor (CaSR) in calcified vessels, with a prevention of arterial CaSR downregulation by 
calcimimetics (143, 144).  
Thus, the aim of this pharmacological study was to investigate the mechanisms of action of 
the Pi-binder lanthanum chloride, compared to gadolinium chloride, and of the calcimimetic 
calindol on the progression of high Pi-induced calcium deposition through their direct effects 
on VSMCs in vitro. 
First of all, we demonstrated that lanthanum chloride, gadolinium chloride and calindol 
prevent VSMC calcium deposition after 7 days of high Pi challenge: indeed, calicium 
deposition was concentration-dependently inhibited by addition of LaCl3, GdCl3 and calindol, 
with a maximal inhibitory effect obtained with 100μM (39.80% of inhibition), 50μM (56.40% 
of inhibition) and 100nM (64.0% of inhibition), respectively. Moreover, we elucidated 
wheather the protective effect of LaCl3, GdCl3 was persistent with the progression of calcium 
deposition, 15 days after challenge VSMCs with high Pi: our results demonstrate that when 
the calcification model is set up, the protective effect of lanthanum and gadolinium is kept 
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(45.10% and 61.20% of inhibition, respectively), and it is independent by any chelating effect 
on phosphate, since Pi levels in the culture medium result unchanged after LaCl3 and GdCl3 
addition at the highest concentration (data not shown). 
Subsequently, we investigated potential intracellular mechanisms of action of these three 
compounds that could be involved in the delay of the progression of high Pi-induced VSMC 
calcium deposition. 
At the beginning, we studied the effect of these three pharmacological treatments on the 
modulation of VSMC lineage markers expression under high Pi conditions. Under normal 
conditions, VSMCs can express smooth muscle lineage markers that represent the 
contractile phenotype, including α-actin and SM22α. It has been intensively elucidated how 
treatment with high Pi causes a loss of smooth muscle lineage markers, preceding 
osteochondrogenic markers up-regulation, such as Cbfα-1/Runx2 and BMP-2, thus inducing 
VSMC phenotypic trans-differentiation. Potentially, this effect may, in part, explain the 
strong association between high serum Pi levels, increased ectopic calcification burden, and 
enhanced cardiovascular morbidity and mortality in CKD and dialysis patients (48, 81, 82).  
We demonstrated that LaCl3 prevents the high Pi-induced down-regulation of two VSMC 
markers, such as α-actin and SM22α . In contrast, GdCl3 and calindol do not affect the 
reduction of the smooth muscle lineage markers induced by high Pi.  
Thus, lanthanum, gadolinium and calindol reduce high Pi-induced calcium deposition in 
VSMCs, but only LaCl3 appears to preserve the normal expression of vascular smooth muscle 
lineage markers. In this study, for the first time, we demonstrated that lanthanum reduces 
vascular calcification by preventing high Pi-induced down-regulation of VSMC lineage 
markers.  
To further elucidate the molecular mechanisms by which these compounds prevent vascular 
calcium deposition, we next analyzed the gene expression of three proteins involved in 
vascular calcification, such as BMP-2, Cbfα1/RUNX2, MGP and the osteonectin protein 
expression (SPARC), all factors actively involved in the osteoblastic differentiation of VSMCs 
when incubated in high Pi media. 
First, we observed a peak in BMP-2 mRNA compared to the relative expression in normal 
cells. 
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Intriguingly, LaCl3, GdCl3 and calindol effectively prevented the high Pi-induced up-regulation 
of BMP-2 mRNA expression. BMP-2 plays an important role in the regulation of bone 
formation, and more recently it has been described its potential role in regulating vascular 
calcification (124). In fact, BMP-2 induces osteoblastic differentiation and mineralization. 
Moreover, calcified human and murine atherosclerotic lesions express BMP-2, whereas 
treatment of bovine VSMCs with BMP-2 enhanced calcium deposition (41). Our studies 
confirm the important role of BMP-2 in regulation of vascular calcification, with the 
possibility to prevent osteoblastic differentiation by pretreatment with lanthanum, 
gadolinium and calindol. 
Afterward, we confirmed that high Pi induces an increase on Cbfα1/RUNX-2 mRNA, but 
LaCl3, GdCl3 and calindol pretreatments are not able to down-regulate the expression of this 
gene deeply involved in osteoblastic differentiation in the vasculature. The fact that these 
pretreatments show any effect on preventing the high Pi-induced increased Cbfα1/RUNX-2 
gene expression may be due to a mechanism affecting other pathways different from 
Cbfα1/RUNX-2, such as Msx2, osterix, and/or Sox9.  
Our in vitro studies suggest that high Pi causes vascular calcification and induces osteoblastic 
VSMCs trans-differentiation by up-regulating both BMP2 and Cbfα1/RUNX-2 gene 
expression. LaCl3, GdCl3 and calindol appear to share a common downstream signalling 
pathway for prevention of vascular mineralization, reducing BMP-2 with no effects on 
Cbfα1/RUNX-2 gene expression. Similar data have been obtained in different experimental 
conditions by Speer et al. (145) in calcified arteries from MGP-/- mice, where Cbfα1/RUNX-2 
mRNA expression was reduced compared to controls, whereas the osteochondrogenic 
transcription factor BMP2 was highly up-regulated. 
Furthermore, we investigated the effects of LaCl3, GdCl3 and calindol pretreatment on Matrix 
Gla Protein (MGP) mRNA levels modulation. MGP is a member of the vitamin-K dependent 
protein family, which has a high affinity for calcified areas and normal media of blood 
vessels, and appears to inhibit locally calcium deposition. Its role in contrasting vascular 
calcification was suggested by the findings that MGP-/- mice develop extensive extra-
skeletal calcification and severe bone disease. Interestingly, both CKD and haemodialysis 
patients have a different distribution of MGP gene polymorphism, with increased risk of 
cardiovascular events as compared to the normal population (146). Surprisingly, we found 
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that LaCl3 completely prevents, GdCl3 does not affect MGP mRNA increase induced by high Pi 
and calindol significantly enhances MGP gene expression compared to high Pi-treated 
VSMCs.  
Our findings suggest that calcium sensing receptor (CaSR) may participate in MGP regulation 
in the vasculature. During the last decade, the CaSR expression in VSMCs has been debated 
(147). More recently, the existence of a functionally active CaSR in VSMCs has been well 
documented (148). Interestingly, Mendoza et al showed that up-regulation of MGP 
expression in bovine VSMCs by other calcimimetics, such as AMG 641, requires high 
concentration of calcium (149). On the contrary, our previous results demonstrate that the 
calcimimetic calindol prevents high Pi-induced vascular calcification independently by 
calcium concentration (150). Our in vitro studies provide a potential mechanism of how 
calcimimetics may prevent high Pi-induced vascular calcification. In fact, calindol prevents 
vascular calcification by delaying the expression of the pro-calcific gene BMP-2 and by up-
regulating the high Pi-induced anti-calcific MGP gene expression. More studies are necessary 
to better elucidate the intracellular mechanism involved in MGP regulation by the 
calcimimetics in VSMCs. 
Lanthanum delays the anti-calcific gene (MGP) expression probably due to the preservation 
of smooth muscle lineage markers and the prevention of VSMC transdifferentiation. In 
contrast, gadolinium does not modify the high Pi-induced elevation of MGP mRNA levels, 
supporting the notion that lanthanum and gadolinium might not share common regulatory 
mechanisms in the pathogenesis of vascular prevention. 
Afterwards, we investigated osteonectin expression, described as a marker of osteoblastic 
differentiation (56). Also on osteonectin protein expression, LaCl3 and GdCl3 show different 
effects: similar to MGP, only lanthanum greatly prevents high-Pi-induced elevations of 
osteonectin protein levels, whereas gadolinium does not. Osteonectin, also known as 
secreted protein acidic and rich in cysteine (SPARC) is a glycoprotein secreted by osteoblasts 
during bone formation, with high affinity for bone mineral calcium. Davies et al. observed 
that protein expression of osteonectin and MGP was higher in patients with systemic 
sclerosis. In particular, SPARC expression was significantly greater in both endothelial cells 
and fibroblasts of those patients with greater calcification (calcinosis) (151). The finding that 
only LaCl3 prevents the increase in ostenectin levels, while GdCl3 show no effects on SPARC 
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enhancement, confirms that these two compounds act with different mechanisms on 
vascular calcification. 
Since apoptosis regulates vascular calcification in vitro, we next investigated the effects of 
LaCl3, GdCl3 and calindol on Axl expression, a membrane tyrosine kinase receptor actively 
involved in this process. Down-regulation of Axl has been associated with calcification, 
whereas the maintenance of its normal levels with prevention of both apoptosis and, thus, 
arterial mineralization (34, 153). In our model, high Pi decreases the expression of Axl. 
Interestingly, LaCl3 preserves Axl protein expression to levels similar to controls. In contrast, 
GdCl3 and calindol fail to prevent the high Pi-induced Axl down-regulation. Collett et al. have 
reported that Gas-6 and its receptor Axl play a key role in osteogenic differentiation of 
vascular pericytes in an autocrine manner (153). More recently, Son et al. demonstrated that 
both fluvastatin and pravastatin may reduce vascular calcification in vitro by inhibiting 
apoptosis, acting on gas6/Axl expression (35). In fact, statins significantly inhibited high Pi-
induced apoptosis and calcification in a concentration-dependent manner in human VSMCs. 
In our studies we demonstrates that LaCl3 prevents high Pi-induced Axl down-regulation. 
These findings indicate that the Axl-mediated survival pathway is a potential target of 
lanthanum effect to prevent vascular calcification.  
Additionally, the actions of BMP-2 may increase apoptosis, so, if the cells pretreatment with 
lanthanum causes a reduction of expression of BMP-2 and an up-regulation of Axl, it is 
plausible that this down-regulation is correlated with the reconditioned expression of the 
anti-apoptotic protein Axl compared to cells challenged with high Pi and without 
pretreatment. For the other two pretreatments, that lead to a down-regulation of BMP-2 
too, the anti-apoptotic pathway involved could be different from Gas6-Axl pathway. 
These in vitro studies may suggest a potential role for lanthanum in preventing vascular 
calcification and osteoblastic differentiation. In the clinical setting, oral lanthanum carbonate 
is used as an efficacious Pi-binder in dialysis patients, even if it is minimally absorbed. On the 
other hand, intravenous gadolinium is used with magnetic resonance, but caution should be 
observed for patients with declined renal function. 
About calcimimetics, several studies investigated the effects of these compounds in animal 
model with vascular calcification (154, 155), including cinecalcet, the only calcimimetic used 
in dialysis patients affected by secondary hyperparathyroidism, even if in vitro experimental 
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data are missing. The data of this study confirm that the activation of the CaSR at the 
vascular level may be important to prevent and reduce VSMC calcium deposition, by both an 
indirect effect on Ca++ and Pi levels and by a direct effect on CaSR activation (143, 144, 156, 
157). 
In summary, LaCl3 prevents high Pi-induced vascular calcification in vitro by affecting VSMC 
osteoblastic differentiation. Several reports have shown that LaCl3 prevents calcium 
deposition in VSMCs (158) and ameliorates vascular calcification in uremic rats (159, 160). In 
our study, we found that lanthanum (I) prevents high Pi-induced calcium deposition in 
VSMCs independently by Pi binding effect; (II) this reduction is a direct effect on VSMCs by 
preserving vascular phenotypic changes, preventing osteoblastic differentiation and 
affecting apoptosis. 
In fact, lanthanum counteracts VSMC transdifferentiation, by preserving smooth muscle 
lineage markers and by delaying the transformation in osteoblastic-like cells through the 
inhibition of BMP-2 and osteonectin elevation. Probably, as a consequence, VSMCs don’t 
need to activate some protective mechanisms against high-Pi, such as elevation in MGP and 
SPARC levels. Interestingly, LaCl3 seems to act also in preventing apoptosis.  
GdCl3 does not share similar mechanisms of action of LaCl3, except for BMP-2, and more 
studies are required to elucidate its action on vascular calcification. 
The calcimimetic calindol prevents high Pi-induced VSMCs calcium deposition by affecting 
VSMC osteoblastic differentiation. In fact, calindol prevents vascular calcium deposition by 
delaying the transformation of VSMCs in osteoblastic-like cells through the inhibition of 
BMP-2 elevation. Nevertheless, VSMCs partially proceed in the differentiation process by 
loosing smooth muscle lineage markers and by increasing Cbfα1/RUNX-2 levels, in spite of 
calindol pretreatment. As a consequence, VSMCs need to activate some protective 
mechanisms against high Pi, such as elevation in MGP levels. Interestingly, calindol does not 
seem to act also in preventing apoptosis.  
So, these three pharmacological treatments have the same final effect on VSMC 
calcification, because they are able to reduce calcium deposition in VSMCs challenged with 
high Pi, but their intracellular action is not the same because they modulate different 
proteins involved in different pathways all implicated in the pathological mechanism of 
vascular calcification. 
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8. CONCLUSIONS 
 
First of all, we studied the modulation of a major non collagenous protein of bone matrix, 
osteonectin, in VSMCs challenged with high Pi for 7 days in vitro and in calcified arteries ex-
vivo, finding results that suggest a pro-calcifying role of this protein. Indeed, our in vitro 
studies demonstrated that there is an association between osteonectin expression and high 
phosphate-induced vascular calcification, suggesting that this protein, probably, acts in 
VSMCs as a pro-calcifying agent and contributes to the process of osteoblastic 
differentiation. Furthermore, osteonectin expression in human arteries ex-vivo is increased 
in VSMCs at the site of arterial calcification.  
Then, we investigated some of the potential biologic processes modulated by high Pi 
treatment that lead to the final event of VSMC calcium deposition, and we discovered that 
extracellular VSMC calcium deposition is the result of a multifactorial process that involves 
all a series of molecular and cellular changes, that culminate in VSMCs loss of their 
contractile phenotype in favour of a simil-osteoblastic transformation, in an increment of 
VSMC apoptosis and in inability of VSMCs to put to use protective pro-survival strategies, 
like autophagy, to try to save themselves from cell death. 
Since high phosphorous has a relevant effect on VSMC calcification, and since cardiovascular 
disease is the most common cause of death in CKD patients, we investigated potential 
strategies to delay the progression of high Pi-induced VSMC calcium deposition. 
First of all, we experimented the “Wash Out” treatment in our in vitro model of vascular 
calcification: surprisingly, we discovered that it is sufficient the total absence or the partial 
decrease of Pi concentration under a so called “trigger threshold” for short and repeated 
periods during the process of calcification to obtain a substantial inhibition of calcium 
deposition. We demonstrated that these protective effects are the result of slowing down 
molecular and cellular processes that are “switch on” by high Pi treatment: indeed, we can 
hypothesize that in the “Wash Out” period, when Pi levels are under “threshold”, cells freeze 
the biological processes that finally lead to calcium deposition because, temporarily, the 
action of Pi is “off”, and so they arrest osteoblastic transformation, apoptosis and “switch 
on” the autophagy protective mechanism. To obtain these benefits is not important the type 
of phosphorous they are challenged with (free Pi or hydroxyapatite) : what is important is 
that they are exposed to under threshold conditions. 
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Then, we investigated the mechanism of action of two drugs CKD patients are treated with in 
the attempt to reduce hyperphosphatemia and to contrast secondary hyperparathyroidism, 
respectively: Lanthanum Chloride (LaCl3) and Calindol. We demonstrated that these drugs 
significantly delay the progression of high Pi-induced VSMC calcium deposition with different 
mechanisms of action: they shared only a mechanism to contrast vascular calcification, that 
is the delay of VSMC osteoblastic transformation; lanthanum is also able to partially prevent 
high Pi-induced apoptosis, while calindol “switch on” the positive modulation of a VSMC 
anti-calcific protein. 
These in vitro discoveries can suggest that it is of relevant importance to control as more as 
possible phosphatemia in CKD patients, even with diet, because high Pi is the most 
dangerous key regulator of vascular calcification in end stage renal disease pathology: so, it 
should be opportune to increment the duration of haemodialysis cycles in CKD patients, 
coupling with, if it is necessary, an adequate therapy, to consent VSMCs to be in contact, as 
more as possible, with under threshold Pi levels.  
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